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ABSTRACT 
The overall goal of the research described in this thesis was to lay a proper 
foundation for designing and conducting efficient control and eradication programs for 
infection with bovine leukemia virus (BLV) in the Canadian dairy industry. 
The objective in Chapter 2 was to identify potentially important risk factors for 
BLV infection in Canadian dairy herds. Of 272 study herds, from 8 provinces of Canada 
and tested during 1998-2003, 78% were BLV-positive. Over 15 management 
determinants for the infection were evaluated. Herds with clinical cases of leukosis 
during the 12 months prior to sampling, as well as herds which purchased animals with 
unknown BLV infection status in the last five years, had a significantly increased 
proportion of BLV-positive cows. Herds from eastern provinces and those not purchasing 
cows in the last five years were more likely to be free from BLV compared to western 
provinces and farms purchasing cows in the last five years. 
The objective in Chapter 3 was to determine the lifetime effects of BLV infection 
on milk production and longevity of dairy cows in Canada. Overall, 4052 cows from 348 
herds were enrolled in a historical cohort study, based on test results from 1998-2003 and 
lactation and culling records post-testing until 2013. Positive cows to BLV had 
consistently greater probability of being culled (or dying) than the negative cows (over 
lifetime lactations 2-7). Only BLV-positive cows with short longevity (2 and 3 lifetime 
lactations) had a significantly lower lifetime milk production compared with their 
negative counterparts. As the cows lived longer (> 3 lactations), the difference in milk 
production between the two cohorts was no longer significant. 
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The objectives of Chapter 4 were: 1) to assess the potential for carryover of 
antibodies against BLV in milk samples obtained from shared meters; and 2) to 
determine if adjustment of the diagnostic test cut-off value would improve the test 
characteristics for meter-collected milk ELISA results. The study included 236 paired 
milk samples from 8 dairy farms in Prince Edward Island collected in 2013. Two 
simultaneous milk samples, one hand-collected at the beginning of milking, and the other 
from the corresponding milk meter, were taken from all lactating cows that were milked 
at the selected meters. The sequence of cows using each meter was recorded. Carryover 
of BLV antibodies at shared milk meters was significant. For low-titer cows, the 
carryover effect was positively associated with the titer of the preceding cows. This could 
result in generating false-positive results in the BLV antibody-ELISA test on meter-
collected samples from dairy herd improvement (DHI) procedures. Based on a new 
optimal cut-point, a suspicious category on the ELISA titers was defined, and a retest on 
the samples falling within this range was recommended to reduce the false positive rate. 
The objectives for Chapter 5 were: 1) to determine the prevalence of BLV 
infection at the herd level using a bulk-tank milk (BTM) antibody ELISA in the Maritime 
region of Canada ; and 2) to develop applied statistical models for predicting within-herd 
prevalence of BLV infection using the BTM antibody levels. To detect BLV infection and 
the antibody levels, a census was implemented on BTM samples from all dairy farms in 
the Maritime region in 2013 (3 monthly rounds of sampling on 623 farms). Another 
round of BTM sampling was coincided with individual cow sampling (all cows that 
contributed milk to the fourth BTM) in 90 selected herds. Herd-level prevalence of BLV 
in the Maritime region was 90.8%. In the individual testing, 30.4% of cows were 
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positive. The statistical models developed in this study were able to predict true within-
herd prevalence of BLV reasonably well based only on the BTM results. The model 
including all BTM tests (4 rounds of sampling) as the predictor had the best fit, although 
the models using 2 and 3 BTM tests provided similar results to 4 repeated tests. 
The focus for Chapter 6 was to assess the diagnostic performance of a 
commercially available ELISA for detecting BLV antibodies in BTM samples collected 
from dairy herds in Eastern Canada in 2013. Of 133 tested herds, 108 herds were found to 
be truly infected. At the resulting optimal cut-point, sensitivity and specificity of the 
BTM ELISA were estimated at 0.972 (0.921 – 0.994) and 1 (0.863 – 1), respectively. 
With the high prevalence of BLV infection across Canada and its detrimental 
economic impacts, pursuing broad-based control programs is necessary. All of the 
findings in the present research could contribute to designing and conducting efficient 
BLV control programs. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
1.1 Enzootic bovine leukosis in dairy cattle 
1.1.1 Background 
Enzootic bovine leukosis (EBL) is known by different names, such as enzootic 
bovine lymphoma, bovine leukosis, infection with bovine leukemia virus (BLV), bovine 
lymphosarcoma, and bovine lymphoma. Leukosis in cattle was originally described in 
Germany in 1871 and reports of the disease in cattle became common following World 
War II and most countries raising cattle have reported the occurrence of the disease 
(Radostits et al., 2006). 
The causative agent of the disease (BLV) is an oncogenic virus from the 
Retroviridae family, the Deltaretrovirus genus. The natural host for the virus is cattle. The 
virus causes a chronic B-cell proliferative disease in cattle and is an important model for 
human T-cell leukemia virus type 1 (HTLV-I) infection because of many shared 
molecular and biological features. Different studies have failed to find pathogenic effects 
of the virus in humans (Fenner et al., 2011). However, a recent case-control study 
suggested that the presence of BLV-related DNA in breast tissue specimens was 
associated with breast cancer (Buehring et al., 2015). Additional research is needed to 
examine this purported association further. 
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All breeds of cattle are susceptible to BLV infection (Radostits et al., 2006). 
Exposure of cattle to BLV results in four possible outcomes: 1) no infection; 2) 
establishment of a permanent infection and development of detectable antibodies for life 
(latent carriers; the most common form); 3) establishment of a permanent infection and 
development of persistent lymphocytosis (PL); or 4) establishment of a permanent 
infection and development of malignant lymphoma (cancer with or without PL). Whether 
the animal becomes infected or develops any other forms of the disease mostly depends 
on the host’s genetic constitution, immune status, and the infective dose of the virus (Da 
et al., 1993; Kabeya et al., 2001). Approximately, 30% of the infected cows proceed to 
the PL stage and fewer than 5% will eventually develop malignant lymphoma during the 
typical lifespans of dairy cattle (Schwartz and Lévy, 1994). 
1.1.2 Prevalence 
Many European countries, including the UK, France, Germany, Spain, the 
Scandinavian countries, Belgium, Switzerland, and The Netherlands, are officially free 
from EBL (Annual EU report, 2013). Some other countries, such as Japan, the United 
States, and Argentina, have actively been working on addressing their BLV problems in 
order to develop cost-effective programs for their dairy industries (Ott et al., 2003; Monti 
et al., 2007; Murakami, 2009; Rodr et al., 2011). 
In Canada, a number of serological surveys have been conducted in different 
provinces to estimate the prevalence of BLV infection. In 1980, the national prevalence 
of BLV infection in Canadian dairy herds was estimated at 40.5%, while only 9.3% of 
tested cattle were positive (Samagh and Kellar, 1982). However, 15 to 20 years later, 
infection levels appeared to have substantially increased. Sargeant et al. (1997) stated that 
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69.6% of the 102 tested dairy herds, and 23% of the 1330 tested cows in Ontario were 
positive to BLV. VanLeeuwen et al. (2001) reported that 70% of herds in the Maritime 
region of Canada had at least one infected cow, while the prevalence of infection at the 
cow level was estimated at 20.8%. Similar studies have revealed a high prevalence of 
BLV infection in Western Canada (VanLeeuwen et al., 2005; VanLeeuwen et al., 2006; 
Scott et al., 2006). 
1.1.3 Transmission and risk factors 
 For a susceptible host to become infected with BLV, virus-infected B 
lymphocytes must gain access to the vascular and/or lymphatic systems. The usual 
method for spread of BLV infection in cattle populations is horizontal transmission, 
through direct and indirect exposure of susceptible animals to the infected lymphocytes 
from blood or, less likely, milk (Ferrer, 1979; Radostits et al., 2006). Some of the typical 
iatrogenic routes of transmission are through contaminated surgical instruments, 
dehorning gouges, ear tattooing pliers, rectal sleeves, and syringes and hypodermic 
needles used between infected and susceptible animals without disinfection. Blood-
sucking insects (e.g. stable fly) may also be involved in the transmission cycle of the 
virus through direct transmission of virus from one animal to another. Although 
transplacental transmission of BLV has been documented, it seems to be relatively 
infrequent (De Jong et al., 2007; Smith, 2009). Congenital infection occurs in 4-8% of 
calves born to BLV-seropositive cows in naturally infected herds (Radostits et al., 2006). 
The contributions of different modes of transmission depend on the frequency and nature 
of BLV exposure, along with the prevalence of infection within the herds (Gutiérrez et 
al., 2011). 
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Prevalence of the infection is positively associated with increasing age. Kale et al. 
(2007) reported that the proportion of infected cows in a Turkish dairy herd gradually 
increased from 52.6% in the first-lactation cows to 66.6% in the fifth-lactation cows. 
Erskine et al. (2012c) proposed a BLV herd profile as a practical tool to determine age-
stratified prevalence of BLV infection in dairy herds. They indicated that BLV within-
herd prevalences (in 113 Michigan dairy herds) were 18.5, 28.8, 39.2, and 44.8% in 1st, 
2nd, 3rd, and ≥4th lactation cows, respectively. 
Poor biosecurity measures, such as introduction of infected cattle to a herd, have a 
significant effect on the subsequent prevalence of infection and the occurrence of clinical 
disease. Any environmental factor or management practice which exposes newborn 
calves to infected blood will increase the risk of infection in the calves; these exposures 
include prolonged close contact between the cow and calf immediately after parturition, 
or any kind of blood-contaminated management interventions such as using contaminated 
needles (Kobayashi et al., 2010; Erskine et al., 2012b). 
Colostrum-based transmission of BLV could also pose a risk of infection to 
neonatal calves, although the significance and magnitude of this risk still remains 
uncertain (Kanno et al., 2014). It has been reported that colostrum and pooled milk (from 
infected dams) increase the risk of BLV transmission, whereas the antibodies in 
colostrum decrease the risk of infection (Romero et al., 1983). Nagy et al. (2007) claimed 
that calves born to BLV-positive cows would be exposed to BLV during parturition, but 
the administration of colostrum from the infected dam would exert a substantial 
protective effect due to the passive antibodies (Nagy et al., 2007). In another study, 
feeding dams’ colostrum to their calves was associated with a decrease in the within-herd 
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seroprevalence of BLV (Kobayashi et al., 2010). Kanno et al. (2014) suggested that 
freezing treatment for colostrum provides a viable means of inactivating the infectivity of 
BLV-infected lymphocytes; however, additional studies to identify the optimal conditions 
for the treatment of pooled colostrum are still required. 
The dynamic of the infection in a cow and the spread of virus within a herd are 
highly dependent on genetic factors of both the virus and the host. Progression of 
infection in a cow to PL is controlled by the bovine major histocompatibility complex 
(MHC). Resistance factors in some animals control the rate of progression of the 
infection and result in reduced numbers of viral-infected cells and lower cell counts, 
which would tend to decrease the risk of BLV transmission (Jubb et al., 1993; Bartlett et 
al., 2014). 
1.1.4 Economics 
Infection with BLV imposes substantial economic loss to dairy herds and 
countries with high prevalence of the infection (e.g. Canada and the USA). Major adverse 
economic impacts of BLV infection include: premature culling, death, and condemnation 
of carcasses at slaughter due to lymphoma, production loss, lower reproductive 
efficiency, impaired immune function and susceptibility to other pathogens, as well as 
trade restrictions imposed on infected cattle and their products (Sandev et al., 2000; 
Bartlett et al., 2014). However, the effects of subclinical BLV infection on production, 
reproductive performance, and longevity/culling rate have been debated in the literature.  
A number of studies have failed to demonstrate a statistically significant 
association between BLV infection and milk production in dairy cows and herds 
(Landston et al., 1978; Huber et al., 1981; Brenner et al., 1989; Da et al., 1993; Tiwari et 
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al., 2007; Sorge et al., 2011). In contrast, detrimental effects of BLV infection on 
production have been reported by others (Emanuelson et al., 1992; Sargeant et al., 1997; 
D'Angelino et al., 1998; Ott et al., 2003; Erskine et al., 2012a). For instance, Erskine et 
al. (2012) reported that each 0.1 increase in the proportion of positive cattle in 104 
Michigan dairy herds was significantly associated with a 115 kg decrease in 12-month 
rolling herd average milk yield. Ott et al. (2003), in a large US study, showed that herds 
with seropositive cows produced 218 kg/cow less milk compared to negative herds. Da et 
al. (1993) demonstrated that positive herds produced 3% less milk per cow. VanLeewen 
et al. (2010) suggested a 7% lower conception rate and longer calving interval in 
seropositive cows compared with their negative counterparts, whereas some other 
researchers could not show any significant association between BLV infection and 
reproduction measures (Brenner et al., 1989; Emanuelson et al., 1992). Although some 
researchers have reported a negative association between BLV infection status and 
longevity of dairy cows (Pollari et al., 1992; Emanuelson et al., 1992; Tiwari et al., 2005; 
Bartlett et al., 2013), they were not able to establish a strong association. 
Measured at the herd level, the direct production losses from EBL in the Canadian 
Maritimes (including provinces of Prince Edward Island (PE), New Brunswick (NB), and 
Nova Scotia (NS)) were conservatively estimated at $806 per year in an average 50-cow 
herd. This does not include costs associated with lost sales of genetically superior 
purebred cattle, which are likely more substantial than the direct production impacts (Chi 
et al., 2002). Furthermore, economic loss per case of lymphoma was estimated to be $412 
in another study (Rhodes et al., 2003). Annual economic losses to the US dairy industry 
associated with BLV were estimated at $285 million for producers and $240 million for 
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consumers; additionally, the subclinical impact of BLV infection on cow longevity was 
not included in those estimations (Ott et al., 2003; Bartlett et al., 2014). 
Most of bull studs protect their export markets by only buying BLV-negative 
bulls because many countries only import semen from studs that are entirely free from 
BLV (Losinger, 2006; Radostits et al., 2006). In Canada, BLV-seropositive bulls are 
barred entry into artificial insemination units. As the concern for BLV increases within 
the world market, it is more likely that cattle buyers confine their purchases only to BLV-
negative replacements. 
A herd with a high prevalence of BLV infection may experience significant losses 
resulting from a high number of clinical cases that have no salvage value. Occurrence of 
the disease can be a major cause of economic loss in high producing elite dairy herds, 
where pedigreed livestock are sold. In these pedigreed herds, individual animals are kept 
to a much older age than in average commercial herds, and because of the increased 
prevalence of lymphoma in cows over 5 years of age, the death losses are likely to be 
severe in the exact group of cows, which is critical to the success of a herd. In addition, 
there is a considerable negative effect on the salability of stock from a herd known to 
have a disease in which genetic susceptibility is thought to play an important role (e.g. 
BLV) (Radostits et al., 2006; Smith, 2009). 
1.1.5 Diagnosis 
1.1.5.1 Lymphoma 
Clinical disease is characterized by the occurrence of multicentric lymphoma, 
with tumors developing rapidly in many sites with an accompanying great variation in 
clinical signs and syndromes. This form is rarely seen in animals less than 2 years of age 
and is most common in the 4-8 year age group. Some of the predominant clinical signs 
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include enlargement of superficial lymph nodes, digestive tract lesions, as well as 
cardiac, nervous, and urogenital systems involvement. The clinical signs and the duration 
of the illness vary with the number and importance of the sites involved and the speed 
with which the tumor masses grow. Neoplastic tumors are identified by histological 
examination of a biopsy specimen, or at necropsy (Schwartz and Lévy, 1994; Smith, 
2009).  
1.1.5.2 Persistent lymphocytosis 
Persistent lymphocytosis (a stable increase in the number of circulatory 
lymphocytes) without clinical signs usually occurs earlier in life, but rarely before 2 years 
of age. Many cows remain in the preclinical stage for years, often for their complete 
productive lifetime without any apparent reduction in performance, but clinical disease 
eventually appears in a proportion of these cows. Persistent lymphocytosis is identified 
through hematologic examinations by observing a permanent increase in absolute number 
of peripheral blood circulating B-lymphocytes (above 10,000/mm
3
) (Radostits et al., 
2006; Smith, 2009). 
1.1.5.3 Common laboratory techniques for detecting BLV infection 
Diagnosis of the infection is made by standard serological (e.g. AGID, RIA, and 
ELISA) or virus detection techniques (e.g. PCR). Cattle infected with BLV will produce 
antibodies against the major internal (p24) and envelope (gp51) virion proteins in their 
serum and milk; hence, antibody-based tests are commonly used for the diagnosis of 
BLV infection in cattle over 6 months of age (Radostits et al., 2006). Once cattle become 
infected with BLV, they remain infected for life and generate a continuous antibody 
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response. This characteristic adds to the validity of antibody-based diagnostic techniques 
for BLV (Monti et al., 2007; Kobayashi et al., 2010). 
From a cost perspective, milk ELISA is a desirable method for BLV-antibody 
detection in large-scale herd surveillance programs which has often been used for 
detection of infected cows and herds (Erskine et al., 2012c). Current commercial ELISA 
kits offer excellent accuracy (nearly 100%) at the individual level application. Both 
serum and milk samples could be used for detection of antibodies. Moreover, the 
excellent analytical sensitivity of ELISA for pooled serum/milk samples allows the 
detection of infected herds with low prevalence (Mammerickx et al., 1985; Ridge and 
Galvin, 2005; Radostits et al., 2006). 
Using bulk-tank milk (BTM) samples, collected by the dairy herd improvement 
(DHI) companies, has become one of the most convenient and economically efficient 
mechanisms for screening for important infectious diseases in dairy cattle (Houe et al., 
1995; Attalla et al., 2010; Sorge et al., 2011). For instance, BTM ELISA has frequently 
been applied to the surveillance of EBL, Johne’s disease, and bovine viral diarrhea 
(Niskanen, 1993; Bitsch and Ronsholt, 1995; Reber et al., 2012; Nielsen and Toft, 2014). 
1.1.5.4 Sporadic bovine leukosis 
A clear distinction must be made between EBL and sporadic bovine leukosis 
(SBL). No association has been demonstrated between SBL and the presence of an 
infectious agent (including BLV). Sporadic bovine leukosis mainly affects animals under 
3 years of age and manifests itself in one of the three following forms: 1) juvenile form in 
calves, less than 6 months, characterized by multiple lymph node enlargement; 2) thymic 
form in yearlings, less than 2 years, characterized by a swelling in the neck causing bloat 
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and edema; and 3) cutaneous form, in cattle 1–3 years old, characterized by the 
development of nodes and plaques in the skin (Radostits et al., 2006; Smith, 2009).  
1.1.6 Immunological implications 
The most obvious immunologic effect of BLV infection is a peripheral blood 
lymphocytosis, which may be indicative of the start of altered immune function. The 
virus is lymphotropic and is believed to cause peripheral blood mononuclear cell 
proliferation and altered apoptosis and cytokine production. Infection with BLV induces 
accumulation of B-lymphocytes in blood and lymphoid tissue with concurrent decreases 
in the percentages of T-lymphocytes (Swenson et al., 2013). Infected T cells increase the 
expression of immunoinhibitory receptors, which in turn enhance the ability of pathogens 
that cause chronic infections to evade immune defenses. This expression of 
immunoinhibitory receptors is positively associated with proviral load (Bartlett et al., 
2014). 
Lymphocytosis is the standard predictor of disease progression, although it is not 
necessarily associated with pathogenic change (Rodriguez et al., 2011). However, several 
reports have suggested that the use of proviral load as an alternative indicator for disease 
progression (Rodriguez et al., 2009; Jimba et al., 2010). When lymphocyte count is not 
available, the lactation number of infected cattle may provide a crude proxy in that older 
animals are more likely to have infections of longer duration and, therefore, their BLV 
infections are more likely to have progressed to the PL stage. Independent of cow age, 
BLV ELISA titers may also indicate a progression of BLV pathogenesis toward 
immunosuppression (Bartlett et al., 2013). Therefore, cows with higher viral load and/or 
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circulatory antibody levels could have a greater potential for spreading the infection 
within a herd. 
1.1.7 Management, control, and eradication 
Bartlett et al. (2014) described all of the reasonable options for dealing with BLV 
infection in the US dairy herds which could fundamentally be extended to the Canadian 
dairy herds. The disease can be eradicated from a herd and even a country, or controlled 
at a low level of prevalence. The option chosen depends primarily on the prevalence of 
infection within a herd, the value of the animals in the herd, and whether a governmental 
indemnity is offered for seropositive cows which are culled and sent to slaughter (Bartlett 
et al., 2014). 
For a comprehensive control/eradication program for BLV infection, four main 
options or a combination of those are suggested: 1) doing nothing; 2) taking appropriate 
control measures; 3) testing and segregation of positive cows; and 4) testing and removal 
(to eradicate BLV). In Canada and the US, it is considered cost-prohibitive to test and 
slaughter all seropositive cattle in many herds because of the high prevalence in those 
herds. Furthermore, many seropositive cows are valuable pedigreed animals, and there 
are no indemnity programs in place. Thus, all control and eradication programs in these 
countries are herd-based and strictly voluntary. Livestock producers are mostly willing to 
adopt control measures because of the economic losses associated with export restrictions 
if their cattle are infected, and the losses due to the occasional clustering of cases of 
lymphoma (Rodríguez et al., 2011). 
Determining the approximate number of infected cows in a herd can be of 
particular importance when a decision on adopting the most suitable control or 
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eradication strategy is to be made. For instance, if only a few positive cows in a herd 
were present, eradication measures (test and removal) could be economically justified. If 
a low prevalence (e.g. 10%) of the infection was expected, then a test and segregation 
strategy could be desirable. The decision rules (farm protocols) for farms with estimated 
prevalence above 20-30% would be similar; usually including standard management 
practices in order to reduce the within-herd transmission of BLV (Casal et al., 1990). For 
herds with medium-to-high levels of within-herd prevalence (e.g. > 20-30%) 
management strategies without removal or segregation for controlling BLV are preferred 
due to the considerable cost (and/or impracticality) of removal and segregation schemes 
(Sandev et al., 2000; Bartlett et al., 2014). Commonly cited management practices for 
minimizing the transmission of BLV in dairy herds are as follows: 
1. Using single-use or disinfected needles and syringes between cows; 
2. Using sterile or disinfected equipment for medical/management interventions 
(e.g. surgery, tattooing, dehorning); 
3. Using single-use or disinfected rectal palpation sleeves; 
4. Avoiding contacts between newborn calves and positive animals; 
5. Not feeding calves with milk or colostrum from positive cows; 
6. Minimizing contacts between different age-groups of animals; 
7. Using artificial insemination (AI) for breeding; 
8. Reducing the populations of blood-sucking insects on the farm; 
9. Segregating or culling BLV-positive cows; 
10. Purchasing BLV-negative replacements. 
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Vaccination could be an effective strategy to control BLV infection (especially in 
high-prevalence regions); however, no commercial vaccine for BLV is currently 
available (Gutiérrez et al., 2014). Many previous attempts to develop an effective vaccine 
against BLV have been unsuccessful, mainly due to incomplete or transient stimulation 
of the host immune response. Some promising results have recently been achieved in 
developing an attenuated, but replication competent, clone that protects against the virus 
in dairy herds (Gutiérrez et al., 2014). An ideal BLV vaccine would have to be non-
infectious, non-oncogenic, and should not interfere with the tests commonly used to 
detect the infection (Radostits et al., 2006). 
Another potential approach to reduce BLV infection in some valuable dairy herds 
could be through the selection of BLV-resistant cattle. Researchers have suggested 
different links between BLV infection and genetic components of cattle. Immune 
responsiveness and heritable resistance, or susceptibility to the infection, are believed to 
be influenced by the host MHC (Da et al., 1993; Radostits et al., 2006; Fenner et al., 
2011). 
In general, control or eradication of BLV infection in Canada should be given 
serious consideration due to: 
 Very high prevalence of the infection at herd and cow levels and its rising trend 
over the past years (as discussed earlier); 
 More countries becoming free from the infection or putting stringent control 
measures in place - this could lead to loss of many export markets and trade 
opportunities in the future; 
 Growing knowledge of production impacts of BLV infection on cattle; 
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 Further concerns regarding the immune function of affected cattle which could 
result in increasing spread of opportunistic infections (e.g. mastitis) (Frie and 
Coussens, 2015); 
 Increasing public concerns regarding the general health and welfare of cattle and 
the quality of their products (Bartlett et al., 2014); and 
 Recent evidence of a possible link between BLV and breast cancer (Buehring et 
al., 2015). 
1.2 Current deficiencies and challenges in controlling enzootic bovine leukosis 
With respect to defining a comprehensive control program for EBL in Canada, 
some of the main challenges that the decision makers are facing include: inadequate 
awareness of the negative impacts and the current burden of the infection on the dairy 
industry, increasing trend of the prevalence in herds and cows, lack of a commercial 
vaccine, as well as costly surveillance methods. To address these challenges and justify 
the necessity for comprehensive control programs in Canadian dairy herds, a few 
fundamental steps must be taken: 1) determining current within-herd prevalence (for 
herd-specific plans) as well as herd-level prevalence (for regional or national programs) 
of the infection; 2) understanding substantial risk factors affecting the distribution of the 
infection within and between herds; 3) estimating the current economic impacts and 
consequences of the infection; and 4) defining the most pragmatic, time/cost-efficient 
control or eradication schemes. Being able to design and introduce efficient monitoring 
tools will assist in motivating authorities and producers to take decisive actions against 
BLV. 
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The prevalence of BLV infection has seen a pronounced rising trend over the past 
decades in Canada (as indicated in section 1.1.2); however, no united regional or national 
control/eradication programs have been pursued to deal with this increasingly important 
issue. In order to design effective control programs, identifying major risk factors of the 
infection is necessary. None of the previous studies has investigated a wide range of 
potential risk factors for BLV on a broad scale in Canada. 
Production effects of BLV infection have been debated in the literature. Some of 
the reasons for obtaining inconsistent findings in the historic studies were: 1) the cross-
sectional nature of those studies; 2) limited number of study cows or herds; 3) in some 
studies, disregarding the structure of data in the statistical analyses; and 4) applying 
production data restricted to the lactations in which BLV testing was performed or a few 
lactations later (as a result, not accounting for possible seroconversions and the 
progression of infection). In addition, there has not been any study investigating the 
lifetime impacts of the infection, which could be more relevant with regard to the chronic 
nature of BLV. To effectively address the BLV problem in every herd, region, or country, 
real-time costs of the infection must initially be estimated (Smith, 2009). 
Another necessary step towards designing efficient control programs is to attain a 
real-time estimate of the number of infected cows in a herd because the management 
options are highly dependent on the within-herd prevalence (Bartlett et al., 2014). To do 
this, a census or at least a representative sample of cows from each dairy herd is required. 
This would not be appealing to the industry and farmers due to financial limitations and 
other important priorities. Hence, to encourage the producers towards adopting 
appropriate control measures, convenient and cost-efficient screening tools are needed. 
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The persistent nature of BLV infection, the continuous antibody response, and the 
absence of commercial vaccination make this infection a reasonable candidate for 
investigating quantitative prediction models for within-herd prevalence (Radostits et al., 
2006; Gutiérrez et al., 2014). Therefore, quantitative examination of BTM samples could 
be an interesting, viable option for reducing costs and saving time/labour in future 
surveillance programs. 
In order to increase the efficiency of monitoring schemes for important infectious 
diseases of dairy cattle, including BLV, milk samples collected by DHI companies are of 
interest. With increasing utilization of DHI diagnostic services on meter-collected 
samples, a legitimate concern has emerged regarding carryover or cross-contamination of 
the samples from shared milking equipment. With respect to sequential milk samples, 
carryover denotes the risk of inclusion of some residual milk from the previous cows in 
the subsequent milk samples (Ordolff, 1997; Lovendahl and Bjerring, 2006).Thus, an 
important question would be - to what extent carryover could influence the transfer of 
diagnostic targets (e.g. BLV-antibodies) in milk between cows, and would that amount of 
transferred material substantially obscure the accurate interpretation of the diagnostic 
tests on those samples? Diagnostic tests with high analytical sensitivity (e.g. ELISA and 
PCR) could produce considerable numbers of false positive results. Antibody-ELISA is 
the most commonly used test in current volunteer screening and surveillance programs 
for BLV and has an excellent analytical sensitivity (Florent et al., 1988; Joozani et al., 
2012); hence, it is possible that even low quantities of carried antibodies could be 
detected by this method. The high rate of false results could in turn lead to making 
inappropriate management decisions, followed by prominent economic losses. There has 
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not been any study focused on the carryover of diagnostic targets in shared milk meters 
and its potential detrimental effects on the success of the current screening and 
surveillance programs. 
In the current screening and volunteer control programs for BLV infection, 
commercial ELISA test kits have widely been used. Applying such tests, particularly to 
the pooled samples (e.g. BTM), might lead to variable levels of uncertainty in the results. 
Several factors, including study region, herd (pool) size, sampling procedures, and 
transfer process can potentially increase variability in test results. Therefore, it has been 
recommended that the validity of diagnostic tests should be evaluated in different 
populations before integrating the tests in large-scale control and eradication programs 
(Christensen and Gardner, 2000; Greiner and Gardner, 2000). However, the commercial 
BLV test which is currently being used in Eastern Canada has not been validated for its 
routine application as a diagnostic test. 
1.3 Thesis objectives/Focus of research 
The research described in this thesis was conducted to address the outlined 
deficiencies and concerns regarding BLV infection in Canada. The overall goal of this 
thesis was to lay a proper foundation for designing and conducting efficient control and 
eradication programs for BLV in Canada (by examining risk factors, productivity 
impacts, and efficient testing strategies for BLV). The specific objectives pursued in 
substantive chapters of this thesis are described below.  
1.3.1 Herd-level risk factors for BLV infection 
In Chapter 2, a cross-sectional study was conducted to identify some of the most 
important risk factors associated with seroprevalence of BLV in Canadian dairy herds. 
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This was the first time that herd-level risk factors for BLV was investigated in Canada on 
such a broad scale. The data used in this chapter were extracted from a comprehensive 
national survey of production limiting diseases, which took place between 1998 and 2003 
in eight provinces of Canada. 
1.3.2 Lifetime impacts of BLV on milk production and longevity 
 In Chapter 3, a historical cohort study was conducted to determine the lifetime 
effects of BLV infection on milk production and longevity of dairy cows in Canada. For 
this study, sub-groups within the national dataset were combined with longitudinal 
production data. 
1.3.3 Carryover effects of BLV antibodies 
In 2013, a new project was designed and conducted in the Maritime provinces to 
determine the present status of the infection, as well as to evaluate cost-efficient 
monitoring tools for BLV (Chapters 4-6). In Chapter 4, an observational study was 
designed: 1) to assess the potential for carryover of BLV antibodies in milk samples 
obtained from shared meters; and 2) to determine whether adjustment of the diagnostic 
test cut-off values would improve the test characteristics for meter-collected milk-ELISA 
results. 
1.3.4 Predicting within-herd prevalence of BLV 
In Chapter 5, a repeated survey was conducted: 1) to determine the prevalence of 
BLV infection at the herd level using a BTM antibody ELISA in the Maritime region of 
Canada ; and 2) to develop applied statistical models for predicting within-herd 
prevalence of BLV infection using the BTM antibody levels. The ultimate goal was to 
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reduce the hassles and costs that pertain to individual cow sampling in estimating the 
within-herd prevalence of the infection. 
1.3.5 Validating an ELISA test at herd level application 
In Chapter 6, combining data from the 2013 study with a similar project 
implemented in Quebec (in 2014), the diagnostic performance of a commercially 
available ELISA (Svanovir BLV gp51-Ab, Svanova, Uppsala, Sweden) for detecting 
BLV-antibodies in BTM samples was assessed. The primary goal was to validate the 
routine application of this test to BLV monitoring in Eastern Canada. 
Finally, Chapter 7 is dedicated to summarizing the conclusions and discussing the 
research limitations and future directions for controlling BLV infection in Canada. In this 
chapter, a provisional example of a comprehensive BLV control program is presented.   
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HERD-LEVEL RISK FACTORS FOR INFECTION WITH BOVINE 
LEUKEMIA VIRUS IN CANADIAN DAIRY HERDS 
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2.1 Abstract 
Enzootic bovine leukosis (EBL) is an economically important infection of dairy 
cattle caused by bovine leukemia virus (BLV). The prevalence of infection in Canadian 
dairy herds is high and continues to increase; however, there has not been a national 
program to control BLV. This cross-sectional study was conducted to identify potentially 
important risk factors for BLV infection on Canadian dairy farms, which is a prerequisite 
to developing an effective control program. 
During 1998 - 2003, based on a stratified two-stage random sampling process, 
315 dairy farms from seven provinces of Canada were selected. Within each farm, 9 to 45 
cows were bled and tested with a commercial serum ELISA kit for BLV-antibodies. A 
comprehensive questionnaire, targeting potentially important herd-level management 
indicators, was successfully administered in 272 herds. A zero-inflated negative binomial 
(ZINB) regression model was built to assess the potential associations between BLV 
seropositivity and a variety of herd-level factors. 
Seventy-eight percent of the herds were identified as BLV-positive (had one or 
more test positive animals). In the negative-binomial part of the final ZINB model, herds 
with clinical cases of leukosis during the 12 months prior to sampling, as well as herds 
which purchased animals with unknown BLV infection status in the last five years, had a 
significantly larger proportion of BLV positive animals. Based on a significant 
interaction between two of the risk factors, changing gloves between cows during 
pregnancy examination was not statistically associated with lower proportion of infected 
cows compared with not changing gloves, in the western Canadian provinces. In the 
logistic part of the model, herds from eastern Canadian provinces and those not 
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purchasing cows in the last five years had increased odds of being free from BLV. The 
high prevalence of infection across Canada should be addressed through the development 
and implementation of a nationwide control program which will address the regional and 
herd-level risk factors for BLV infection identified in this study. 
2.2 Introduction 
Enzootic bovine leukosis (EBL) is an economically important infection of dairy 
cattle worldwide, which is caused by bovine leukemia virus (BLV). Clinical signs of the 
disease are not displayed by most infected cattle; fewer than 5% of them will eventually 
develop malignant lymphoma. Premature culling, death, and condemnation of carcasses 
at slaughter due to lymphoma, as well as trade restrictions imposed on infected cattle and 
their products are among the most significant losses attributed to the disease (Sandev et 
al., 2000; Bartlett et al., 2014). 
The usual method for spread of BLV infection in cattle populations is horizontal 
transmission through direct and indirect (e.g. iatrogenic) exposure of susceptible animals 
to the infected lymphocytes from blood or less likely milk. Although transplacental 
transmission of BLV has been documented, it seems to be infrequent (Radostits et al., 
2006; Gillet et al., 2013). The contribution of different haematogenous modes of 
transmission depends on the frequency and nature of BLV exposure, along with the 
prevalence of infection within the herds (Gutiérrez et al., 2011). In order to control the 
infection, it is necessary to properly determine and inhibit the important modes of 
transmission. Once cattle become infected with BLV, they usually remain infected for 
life and have a continuous antibody response (Monti et al., 2007; Kobayashi et al., 2010); 
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this characteristic of the infection adds to the validity of antibody-based diagnostic 
techniques. 
The 2013 annual report of the European Union on bovine and swine diseases 
declared that many European countries including the UK, France, Germany, Spain, the 
Scandinavian countries, and the Netherlands were officially free from EBL (Annual EU 
report, 2013). Other countries, such as Japan, the United States, and Argentina, have been 
actively working on addressing their BLV problems in recent years in order to develop 
effective programs for their dairy industries. Control of EBL at the national level usually 
consists of one or more of the following three approaches: management interventions; 
test and segregation; and test and slaughter (Ott et al., 2003; Rodríguez et al., 2011; 
Murakami et al., 2011; Bartlett et al., 2014). Management interventions can only be 
effective if the most important management determinants are identified, well understood, 
account for a sizable attributable risk and allow easy and economical remediation 
(Erskine et al., 2012b). 
In different provinces of Canada, there have been a number of serological studies 
which have estimated the prevalence and impact of BLV infection. In 1980, national 
prevalence of BLV infection in Canadian dairy herds was estimated at 40.5%, while only 
9.3% of tested cattle were positive (Samagh and Kellar, 1982a). However, 15 to 20 years 
later, infection levels appeared to have increased, substantially. Sargeant et al (1997) 
indicated 69.6% of the 102 tested dairy herds, and 23% of the 1330 tested cows in 
Ontario were positive to BLV. VanLeeuwen et al (2001) reported that 70% of herds in 
the Maritime region of Canada (including provinces of Prince Edward Island, New 
Brunswick, and Nova Scotia – forming part of the database for the current study) had at 
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least one infected cow, while the prevalence of infection at the cow-level was estimated 
at 20.8%. Similar studies revealed a high herd-level prevalence of BLV infection across 
Canada (VanLeeuwen et al., 2005a; VanLeeuwen et al., 2006; Scott et al., 2006). 
Measured at the herd level, the direct production losses from EBL in the Maritime 
provinces have been conservatively estimated at $806 per year in an average 50-cow herd 
(Chi et al., 2002). This does not include costs associated with lost sales of genetically 
superior purebred cattle, which are likely more substantial than the direct production 
impacts.  
Since there is no nationwide program for controlling EBL in Canada, this cross-
sectional study was conducted to identify some of the most important risk factors 
associated with seroprevalence of BLV in Canadian dairy herds. This is the first time that 
herd-level risk factors for BLV have been investigated in Canada on such a broad scale. 
2.3 Materials and methods 
The data set was extracted from the Canada-wide surveys of production limiting 
diseases that took place between 1998 and 2003 on dairy farms of Prince Edward Island 
(PE), New Brunswick (NB), Nova Scotia (NS), Ontario (ON), Saskatchewan (SK), 
Quebec (QC), Manitoba (MB), and Alberta (AB). The primary objective of the project 
was to obtain reasonably valid estimates for herd-level prevalence of infection with four 
pathogens of interest (BLV, Bovine Viral Diarrhea Virus, Mycobacterium avium 
subspecies paratuberculosis, and Neospora caninum) in all of the participant provinces. 
British Columbia (BC) did not participate in the survey, and Ontario did not administer 
the questionnaire due to logistical reasons (e.g. funding, coordination, timing). Therefore, 
those provinces were not included in the present risk-factor study. A political map of 
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Canada displaying its provinces and territories is presented in Appendix A. The following 
subsections provide a summary of the sampling and testing protocols. 
2.3.1 Herd and animal selection 
A stratified two-stage random sampling procedure was applied. Sample size was 
first based on the calculations carried out for the Atlantic provinces, and then adjusted for 
the other provinces with respect to the number of available herds, herd size, budget, and 
other logistics (VanLeeuwen et al., 2001; Tiwari et al., 2009). The minimum number of 
cows required from each herd to result in a reasonable estimate of within-herd prevalence 
was obtained based on the following assumptions: an average herd size of 45 lactating 
cows, within-herd prevalence of 0.05, and confidence level of 0.95. Therefore, 
approximately 30 cows per herd were needed. In herds with less than 30 cows, all cows 
were bled and tested. The minimum number of herds required from each province to get 
reasonably valid estimates for herd-level prevalence of the infection in all of the 
participant provinces was then calculated based on the following assumptions: an 
expected herd-level prevalence of 0.70, acceptable relative error of 0.10, and confidence 
level of 0.95. 
2.3.2 Sample collection 
During the summer of 1998 in Atlantic Canada (PE,NB, and NS), participating 
dairy herds were randomly selected, using computer-generated random numbers, from all 
herds on monthly milk testing (67% of all dairy herds in Canada) through the regional 
dairy herd improvement (DHI) organization until 90 herds were recruited, 30 herds from 
each province. These herds met the other herd-level inclusion criteria, including 
willingness to provide cattle for blood samplings, allowing the blood to be tested for 
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antibodies, and releasing DHI data to the research team. Subsequently, similar herd-level 
inclusion criteria and sampling procedures were used to recruit 44, 75, 40, and 66 herds 
from the provinces of SK, QC, MB, and AB in 2001, 2002, 2002, and 2003, respectively 
(overall, 315 herds were tested for BLV antibodies). Using computer-generated random 
numbers, a median of 30 cows (range: 9 – 45) were randomly selected for blood 
collection from every herd. 
2.3.3 Laboratory testing 
Within 24 hours after collection, the blood samples were centrifuged, sera were 
harvested, and stored at -20
oC
 until all of the samples for that province were collected and 
prepared for testing. The test used for detecting BLV antibodies was an ELISA (IDEXX 
Corporation, Westbrook, ME, USA; sensitivity = 0.985, and specificity = 0.999). The 
testing for all provinces except QC was conducted at the national BLV testing laboratory 
of the Canadian Food Inspection Agency in PE, and the BIOVET Inc. laboratory in QC 
was utilized for the dairy farms from QC, as requested by the director of the QC portion 
of the study. A cow was considered to be infected with BLV if the serum-to-positive ratio 
was ≥ 0.5, as recommended by the manufacturer of the test kit. Every herd with at least 
one infected animal was defined as being positive. 
2.3.4 Data collection and management 
Herd-level demographic and management data related to the four mentioned 
production limiting diseases were collected through personal interviews with owners or 
managers at each farm.  Only questions addressing issues which were hypothesized to be 
related to BLV seropositivity, such as “transmission of disease through blood”, were 
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extracted and included in the final data set. Examples of the question details can be found 
elsewhere (Tiwari et al., 2009).  
Additional variables were generated to enable more complete risk factor analysis. 
The region where herds were located was defined as a dichotomous variable: east (PE, 
NB, NS and QC) versus west (SK, MB, and AB). Contact index was generated as a 
dichotomous variable such that a herd was classified as positive if, over the past five 
years, any dairy cattle in the herd had contact with cattle from another herd(s) through at 
least one of the following routes: 1) shared pastures, 2) contract raising of young stock, 3) 
lending cows/bulls, and 4) borrowing cows/bulls. The median age of animals in each 
herd was the third derived variable of interest. Age of the animals (in months) was 
retrieved from the DHI database for each herd. Descriptions of all independent variables 
are presented in Table 2.2. 
2.3.5 Statistical analyses 
The data were analysed as follows using Stata 13.1 (StataCorp, College Station, Texas, 
USA). Descriptive statistics (e.g. means, standard deviations, medians, proportions) were 
calculated for all independent variables to describe the population and to assist in the 
subsequent modeling process.  
Because 59 herds were BLV-negative, a zero-inflated negative binomial (ZINB) 
regression (Dohoo et al., 2009; Hilbe, 2011) was applied to determine the univariable 
associations between each independent variable and the proportion of BLV-seropositive 
cattle on each farm. ZINB models deal with an excessive number of zero counts by 
simultaneously fitting both binary (usually logistic regression) and count (negative 
binomial) models. The outcome in the negative binomial (count) part of the ZINB model 
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was converted from the number of BLV-seropositive cows to the proportion of 
seropositive cows in a herd (seroprevalence) by adding the number of tested cows in each 
herd as an exposure term to the models. The association between an independent variable 
and this outcome was described in terms of an estimated coefficient and its corresponding 
confidence interval, and of a prevalence ratio in the final multivariable ZINB model. The 
outcome in the logistic part of the ZINB model was the odds of a zero count or being 
uninfected; therefore, coefficients have an opposite interpretation to what would be 
expected in an ordinary logistic regression model. Region was forced into all of the 
analyses as a potential confounder.  
Those independent variables for which the P-value was ≤ 0.15 in either part of the 
univariable analysis were retained for inclusion in the multivariable model. A backward-
elimination strategy was used to build the multivariable model, with a P-value of less 
than 0.05 (two-tailed) to retain variables. Variable selection was made considering: 1) a 
theoretical causal web depicting possible relationships among the independent variables 
and the outcome (Figure 2.1); 2) P-values of the variables in either part of individual 
ZINB regressions; and 3) correlations among independent variables. All potential two-
way interactions between the variables in the multivariable model were assessed, and 
significant (P < 0.05) interactions were retained in the final model. 
Finally, in order to assess the predictive ability of the final ZINB model, observed and 
predicted probabilities of the number of BLV infected animals in the herds were 
generated and compared. In addition, the Vuong test was applied to compare the 
goodness-of-fit of the ZINB model versus an ordinary negative binomial regression 
model containing the same variables. 
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2.4 Results 
Over 95% of the randomly selected herds agreed to participate in the blood 
sampling and met the inclusion criteria. Complete questionnaires were available for 272 
farms, with 59 of those being BLV negative. Table 2.1 has summarized distribution and 
descriptive statistics for the 272 selected herds and a frequency distribution of the within-
herd seroprevalence is presented in Figure 2.2. Thirty positive herds had a within-herd 
prevalence of less than 10% while seven herds had more than 90% of their animals 
infected. Based on the univariable analyses, four independent variables (bolded in Table 
2.2) were retained for the multivariable modeling. 
Of 272 farms, 235 were included in the final modeling process due to no missing 
data. In the negative binomial part of the final ZINB model, representing factors 
associated with spread of infection within the farms, herds with clinical cases of leukosis 
over the last 12 months prior to sampling had a 1.69 times higher within-herd 
seroprevalence (P = 0.001) compared to the herds without such history. Purchasing 
animals without confirmation of freedom from BLV infection in the last 5 years was also 
associated with  a larger proportion of positive animals (P < 0.001) than farms not 
purchasing cows or farms purchasing cows but only if BLV-negative. Among the two-
way interactions, the interaction between “Region” and “Changing gloves for pregnancy 
check” was found to be statistically significant in the count part of the model (P = 0.002); 
changing gloves between animals in the eastern region was associated with a higher 
proportion of infection compared to the other combinations. In western provinces, 
changing gloves was not statistically associated with the proportion of infection within 
the herds (Table 2.3).   
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In the logistic part of the model, representing factors associated with spread of 
infection between the farms, herds in the western region had approximately 3 times 
higher odds of being infected as compared with their eastern counterparts (P = 0.006). 
Not purchasing cows was positively associated with the odds of herds being free of BLV; 
farms not purchasing cows in the last 5 years had 6.5 times lower odds of being infected 
(P < 0.001) compared with the farms purchasing cattle without a BLV test requirement.    
As illustrated in Figure 2.3, observed and predictive proportion of infected cattle 
within the herds, based on the ZINB model, were reasonably compatible. Moreover, the 
Vuong test produced a highly significant P-value of 0.0002, indicating that the ZINB 
model was clearly superior to a non-inflated (ordinary) negative binomial model. 
2.5 Discussion 
This study evaluated a wide range of potential herd-level risk factors for BLV in 
dairy farms from across Canada for the first time. Applying a zero-inflation part to the 
model demands the possibility of two mechanisms for producing zero counts, other than 
having extra zero counts (Dohoo et al., 2009; Hilbe, 2011). In our study, we did have 
these two known mechanisms: 1) a number of the herds (54/235) were defined as 
negative in the final model based on their serological results and could have been truly 
free from BLV (certain zeroes in the logistic part); 2) negative herds might theoretically 
have been positive but we were not able to detect those because of different reasons, 
including our sampling method and imperfect laboratory tests; therefore, these herds were 
incorporated in the count part of the model. 
The results clearly indicated a high prevalence of BLV infection across the seven 
study provinces in Canada at the time of sample collection, and this prevalence likely is 
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still increasing. For instance, in PE, herd-level prevalence of BLV was 49.2% in 1989 
(Richardson and Macaulay, 1992), increased to 63.3% in 2001 (VanLeeuwen et al., 
2001), and is currently at 90% based on a survey of bulk-tank milk in all dairy herds in 
the province completed in 2013 (Chapter 5). 
Western Canada had a higher seroprevalence of BLV compared to Eastern 
Canada, which could partly be due to the presence of larger herds in this region. In larger 
herds, there might be an increased chance of animal exposure to the virus, especially 
through haematogenous modes of transmission, such as reusing needles for injections, 
and more intensive reproductive and vaccination programs.  The exact number of cattle in 
the herds was not available; hence, we used the number of registered cows as an indirect 
surrogate for herd size, which was found to be not associated with the BLV-
seropositivity. Other researchers could not find any significant effect of herd size on the 
prevalence of BLV (Sargeant et al., 1997a; Kobayashi et al., 2010; Murakami et al., 
2011). In a Danish study (Gottschau et al., 1990), herd-level prevalence of BLV 
increased as herd size (in a categorical order) increased. In contrast, when a herd was 
infected, the proportion of positively tested cattle within that herd decreased with 
increasing herd size. It should be noted that the herd-level prevalence of EBL in Denmark 
at the beginning of the study (1970) was very low (<0.3%), which is far less than the 
previously mentioned studies.  
Purchasing cows without knowledge of their infection status, not only for BLV 
but also for other important contagious diseases of cattle is a recognized risk factor for 
transmission between herds (Casal et al., 1990; Radostits et al., 2006). Purchasing 
infected animals would allow these individuals to act as a source for the introduction of 
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the disease agent to non-infected herds, and because infection is permanent this provides 
a continuous source for spreading BLV within infected herds. In this study, only 65 farms 
(25%) had not purchased any cows over the specified period of time, and among the 
farms with a purchasing history, the majority of them (88%) had not tested their 
purchased animals for BLV. In order to control a contagious disease such as BLV, 
producers should either raise their own replacements or buy test-negative animals. 
Veterinarians should be recommending to their clients the testing of purchased animals 
for BLV, along with other important infectious diseases. 
The association between changing rectal gloves for pregnancy check between 
animals and seroprevalence of BLV depended on the region in which the herds were 
located; changing gloves between animals was not statistically associated with the 
proportion of infected animals in western Canada. In the eastern herds, changing gloves 
between animals was associated with a greater proportion of positive animals than not 
changing gloves between animals. The latter finding was contrary to what would be 
expected, given the current understanding of the role of rectal examination in spreading 
BLV infection between animals in a herd (Divers et al., 1995). Rectal examination is a 
potential route of transmission for BLV, but transmission by rectal gloves is also related 
to other factors such as number of palpations with one common glove, level of 
contamination of the glove with infected blood lymphocytes, and age of the animals 
(Radostits et al., 2006). Changing rectal gloves between cows is certainly something that 
veterinarians can employ for preventing the spread of some infectious diseases, such as 
BLV, between cows. It is also possible that highly infected eastern herds with known 
status of the infection were using this strategy to attempt to prevent further spread, or that 
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there are differences in perceived importance of the disease or employed control 
measures between the two regions. 
The present study did not find significant associations between BLV 
seropositivity and some well-described risk factors for BLV involving transmission 
through infected blood, such as multiple-use of needles. One likely explanation for this 
could be the possible change in management behaviour of the farmers subsequent to 
identifying clinical cases of BLV-related diseases in their herds (e.g. lymphoma). For 
instance, we found a significant association between having clinical cases of BLV over 
the year prior to our study (Table 2.2, which was associated with BLV prevalence in our 
model as well) and using single-use needles in every injection (results not shown here), 
suggesting that those herds which applied single-use needles were more likely to have 
clinical cases. However, after having a clinical case of BLV, farmers might have 
modified their BLV-control strategies towards posing a lower risk of infection 
transmission at the time of this study. Therefore, even with applying recommended 
strategies for controlling the disease, they still demonstrated a high prevalence of 
infection at the time of completing the questionnaires. This issue is clearly driven by the 
inherent limitation of cross-sectional studies (reverse causation); such studies are good at 
establishing association, but poor for ascertaining causality. Reports have also suggested 
that the importance of haematogenous transmission is variable and may depend on the 
frequency and the nature of exposure (Gutiérrez et al., 2011; Erskine et al., 2012b). 
Future prospective studies measuring both management activities and BLV status would 
be useful for quantifying the risk associated with management factors.  
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Using gouge dehorning has been identified as another important risk factor in 
transmitting BLV (DiGiacomo et al., 1985; Radostits et al., 2006; Kobayashi et al., 2010; 
Erskine et al., 2012b). In the univariable analysis, application of techniques other than 
gouge dehorners for dehorning was associated with a decreased risk of BLV-positive 
animals. However, this association was not statistically significant in the final model.  
Using pooled milk to feed the calves, having contact with other animals and herds 
in any of the ways as defined in the “contact index”, and having long waiting times 
before separation of newborn calves from their dams in maternity pens were among other 
management factors which were found to be not statistically associated with increased 
prevalence of BLV in the univariable analyses (p > 0.15). 
Of the 272 herds under study, 235 were included in the final multivariable 
modeling process. The incomplete information from 37 farms might be attributable to the 
exhaustive structure of the questionnaire evaluating the four production limiting diseases 
at the same time. The loss of these herds may have introduced a bias to the results; 
however, similar distribution of the within-herd prevalence and other descriptive statistics 
between the 235 and 37 herds suggested that this potential bias was unlikely to be 
substantial. For instance, BLV prevalence for the final 235 herds was 77%, which was 
very close to the prevalence for the 272 herds (78.3%). 
Although there is always a possibility for misclassification bias in seroprevalence 
studies, this issue would not substantively affect our analyses for the following reasons: 
1) ELISA tests for detecting antibodies against BLV are highly reliable; not only due to 
very high sensitivity and specificity of the test (nearly perfect), but also because of the 
permanent nature of BLV infection and relatively stable antibody response (Radostits et 
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al., 2006); 2) reasonable numbers of animals sampled from each herd led to high herd 
sensitivities in most of our herds, and only a few herds (5/272) had herd sensitivities less 
than 0.90; and 3) we applied a ZINB model methodology, which effectively deals with 
the two scenarios mentioned earlier (i.e. certain and potentially negative herds). Overall, 
we believe the effect of potential misclassification would be minimal on the presented 
associations in this study. 
2.5.1 Conclusions 
The Canadian dairy industry requires a more serious response to its high BLV 
prevalence. In general, moving towards closed herds in the cattle industry will be an 
efficient way to control different contagious diseases, wherever possible. National, 
regional, and herd-specific BLV control programs should not only be focused on 
inhibiting virus transmission between herds by purchasing BLV-infected replacement 
animals, but also focused on decreasing BLV spread between cows (within herds) 
particularly in herds with high prevalence of BLV infection. Additional research is 
required to establish the relative risk associated with various methods of within herd 
spread. Applying proper count data models is recommended to extract all of the available 
information in different data sets on risk factors for infectious diseases of dairy cattle.    
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Table 2.1. Distribution of total and bovine leukemia virus (BLV)-seropositive dairy herds 
which had completed questionnaires in seven Canadian provinces during 1998-2003. 
 
Region 
 
Province 
Herds Number of tested  
cattle in the herds 
Median prevalence 
in infected herds 
n Infected
 a
(%)
b
 Min Median Max  
East Prince Edward Island 30 19 (63.3) 18 30 34 16.7 
 Nova Scotia 30 23 (76.7) 9 30 31 13.8 
 New Brunswick 30 21 (70.0) 21 30 31 42.8 
 Quebec  34 21 (61.8) 20 20 20 35.0 
West  Manitoba 39 37 (94.9) 20 30 32 63.3 
 Saskatchewan  43 37 (86.0) 31 40 45 43.9 
 Alberta 66 55 (83.3) 30 37 37 35.1 
Total  - 272 213 (78.3) 9 30 45 36.7 
a 
Herds having at least one positive animal were considered infected. 
b 
% is the number of infected herds divided by the total number of tested herds, by 
province.  
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Table 2.2. Distribution of the variables of interest and results of univariable associations 
between each variable and bovine leukemia virus (BLV) infection in 272 Canadian dairy 
herds during 1998-2003
a
. 
Variables of interest with their corresponding levels n b Count part Binary part 
  β (95% CI)c β (95% CI)c 
1. Region d 272   
     Eastern provinces 124 - - 
     Western provinces 148 0.36 (0.13; 0.59) -1.12 (-1.83; -0.42) 
2. Number of registered cows in the herd 238   
     <50 111 - - 
50-100 94 -0.16 (-0.43; 0.12) -0.41 (-1.19; 0.38) 
>100 33 -0.15 (-0.52; 0.23) -1.26 (-3.15; 0.62) 
3. Median age of tested animals within each herd (months) 247   
<40 83 - - 
40-50 105 -0.08 (-0.35; 0.19) 0.04 (-0.85; 0.93) 
>50 59 -0.01 (-0.34; 0.31) 0.35 (-0.61; 1.31) 
4. Having clinical cases of leukosis in the last year (before testing) d 238   
     No 211 - - 
     Yes 27 0.43 (0.08; 0.77) -1.85 (-4.25; 0.54) 
5. Purchasing cows and their BLV status requirements over the last 5 years d 256   
     Purchased and no testing needed  168 - - 
     Purchased and negative status needed  23 -1.05 (-1.57; -0.53) 0.94 (-0.49; 2.37) 
     No purchases 65 -0.27 (-0.55; 0.01) 1.86 (1.05; 2.68) 
6. Using new needles for every injection 253   
No 103 - - 
No, but disinfecting between animals 58 0.12 (-0.17; 0.42) 0.15 (-0.77; 1.08) 
Yes 92 0.28 (-0.02; 0.58) -0.31 (-1.19; 0.57) 
7. Using new syringes for every injection 249   
     No 153 - - 
     Disinfecting between animals or using new syringes  96 -0.06 (-0.26; 0.15) -0.07 (-0.71; 0.56) 
8. Method of dehorning animals  255   
Cutting without disinfection between animals 131 - - 
Cutting with disinfection between animals 39 -0.05 (-0.39; 0.29) -0.49 (-1.85; 0.86) 
Non-cutting methods 85 -0.16 (-0.52; 0.19) 0.52 (-0.47; 1.51) 
9. Disinfecting hoof trimming equipment between animals 249   
     No 225 - - 
     Yes 24 0.09 (-0.33; 0.51) 0.29 (-0.81; 1.39) 
10. Disinfecting instruments used for extra teat removal between animals 253   
     No 90 - - 
     Yes 118 0.007 (-0.26; 0.28) 0.22 (-0.71; 1.15) 
     Not applicable  45 -0.11 (-0.45; 0.23) 0.34 (-0.74; 1.42) 
11. Changing gloves used for pregnancy check between cows e  253   
No 187 - - 
Yes 66 0.29 (-0.02; 0.61) -0.18 (-1.01; -0.65) 
12. Changing gloves used for artificial insemination 250   
No 40 - - 
Yes 210 0.09 (-0.23; 0.41) -0.32 (-1.26; 0.63) 
13. Using pooled milk from all cows to feed the calves 255   
No 64 - - 
Yes 191 0.02 (-0.24; 0.28) 0.44 (-0.45; 1.32) 
14. Time of separating newborn calves from their dams (hours) 250   
<6 152 - - 
6-12 58 0.17 (-0.11; 0.45) 0.21 (-0.63; 1.05) 
>12 40 0.23 (-0.11; 0.55) -0.05 (-1.02; 0.93) 
15. Contact index f 256   
No 162 - - 
Yes 94 0.08 (-0.16; 0.31) 0.02 (-0.70; 0.74) 
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a
 Based on a zero-inflated negative binomial  regression analysis for each variable in both 
parts of the model at the same time and accounting for the number of tested cows in the 
herds, and region. 
b
 Total and subgroup number of herds for each factor.  
c
 β is the coefficient of each explanatory variable with the corresponding 95% confidence 
interval.  
d
 P≤0.15 in both parts, so succeeded to both parts of the multivariable model. 
e
 P≤0.15 in only count part of the model, so succeeded to the count part of the 
multivariable model. 
f
 “Contact index” was defined as a dichotomous variable such that a herd was classified 
as positive if, over the past five years, any dairy cattle in the herd had contact with cattle 
from another herd(s) through at least one of the following routes: shared pastures, 
contract raising of young stock, and lending or borrowing cows and bulls.  
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Table 2.3. Output of the final zero-inflated negative binomial (ZINB) model assessing the 
risk factors of bovine leukemia virus (BLV) infection in 235 Canadian dairy farms during 
1998-2003. 
Count part (Negative Binomial) PR
a 
SE 95% CI P-value 
1. Having clinical cases of leukosis over the last 1 year    0.001 
No -
b 
- -  
Yes  1.69 0.28 1.22-2.33  
2. Purchasing cows and their BLV status requirement over the last 5 
years   
   <0.001
c
 
Purchased and no testing needed  - - -  
Purchased and negative status needed  0.33 0.08 0.19-0.55  
No purchases 0.83 0.12 0.62-1.19  
3. Region * Changing gloves used for pregnancy check between 
animals 
d 
   0.002
c
 
     East * no - - -  
East * yes  1.87 0.34 1.31-2.69  
West * no  1.70 0.26 1.26-2.29  
West * yes  1.50 0.50 0.78-2.88  
Binary part (Logistic)   OR
e 
SE 95% CI P-value 
1. Region    0.006 
Eastern provinces - - -  
Western provinces 0.31 0.13 0.14-0.71  
2. Purchasing cows and their BLV status requirement over the last 5 
years   
   <0.001
c
 
     Purchased and no testing needed  - - -  
     Purchased and negative status needed  2.54 1.85 0.61-10.61  
     No purchases 6.51 2.73 2.86-14.82  
a
 Prevalence Ratio (seroprevalence of BLV infection in a subgroup of herds divided by 
that in the corresponding reference subgroup of herds).  
b
 All reference categories displayed by ‘-’ sign.  
c
 Overall P-value for the factor’s effect. 
d
 Interaction term between region and changing rectal gloves, which was significant 
overall (P = 0.002).  
e
 Odds Ratio (please note that the interpretation of OR in the logistic part of a ZINB 
model is opposite to an ordinary logistic model).  
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Figure 2.1. A theoretical causal web for seroprevalence of bovine leukemia virus (BLV) 
infection in 272 Canadian dairy farms during 1998-2003. To keep the web as simple as 
possible, all management factors were considered as a block, including “purchasing 
cows”, “median age”, “using new needles and syringes for every injection”, “methods of 
dehorning”, “disinfecting hoof trimming and extra teat removal tools between cows”, 
“changing gloves for pregnancy check and artificial insemination between cows”, “Using 
pooled milk from all cows to feed the calves”, “Time of separating newborn calves from 
their dams”, and “contact index”. “Clinical BLV” was defined as “having clinical cases 
of leukosis in the last year before testing”. 
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Figure 2.2. Frequency distribution of within-herd seroprevalence of bovine leukemia 
virus (BLV) infection in 272 Canadian dairy farms during 1998-2003. 
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Figure 2.3. Observed and predicted probability distributions for the number of positive 
animals within the herds, based on the final zero-inflated negative binomial (ZINB) 
model in 235 Canadian dairy farms. X-axis: range for the number of positive cows in the 
herds; Y-axis: the results from two different ZINB probability equations (or proportion of 
observations) (the original and after fitting the final model), when using each X as an 
input.   
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LIFETIME EFFECTS OF INFECTION WITH BOVINE LEUKEMIA 
VIRUS ON MILK PRODUCTION AND LONGEVITY OF 
CANADIAN DAIRY COWS 
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3.1 Abstract  
Enzootic bovine leukosis (EBL) is an economically important disease of dairy 
cattle caused by bovine leukemia virus (BLV). The economic impacts of the infection 
have been debated in the literature. The present study was conducted to determine the 
lifetime effects of BLV infection on milk production and longevity of dairy cows in 
Canada. 
The data were aggregated from a combination of two data sets: 1) BLV serum 
ELISA test results from Canada-wide surveys of production limiting diseases which took 
place between 1998 and 2003 in 8 provinces, and 2) longitudinal production data for all 
cows in the former study, extracted from the Canadian dairy herd improvement database. 
All participant cows had been culled or died by the onset of this study. A historical cohort 
study was designed, including cows which tested positive to BLV-antibodies in their first 
lactation (positive cohort, n = 1858) and cows which tested negative in their second or 
later lactations (negative cohort, n = 2194). To assess the impacts of infection with BLV 
(X) on longevity (Y1: the number of lifetime lactations), a discrete-time survival analysis 
was carried out. The effect of BLV on the lifetime milk production (Y2: the sum of all life 
305-day milk production) was evaluated using a multilevel linear regression model. 
Overall, 4052 cows from 348 herds met the eligibility criteria and were enrolled 
in the study. In the longevity model, the interaction term between time (the lactation 
number) and BLV-status was significant. Cows which were positive to BLV had 
consistently greater probabilities of being culled (or dying) than the negative cows. In the 
milk production model, the interaction term between BLV-status and longevity of the 
cows was highly significant; indicating that lifetime BLV effects on the total milk 
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production was dependent on the lactation in which the study cows were culled or died. 
Infected cows with 2 and 3 lactations showed significantly lower life milk productions [-
2554 kg (-3609 to -1500) and -1171 kg (-2051 to -292), respectively] compared with their 
negative counterparts with 2 and 3 lactations. Overall, as the cows lived longer (> 3 
lactations), the differences in life milk production between the two cohorts were no 
longer significant. With the high prevalence of BLV infection in Canadian dairy cows 
and its detrimental economic impacts, pursuing a broad-based control program in Canada 
is necessary. 
3.2 Introduction 
Enzootic bovine leukosis (EBL) is an economically important disease of dairy 
cattle across the world. The causative agent of EBL is a retrovirus, bovine leukemia virus 
(BLV). The virus is transmitted through infected blood lymphocytes (Gillet et al., 2013). 
Once cattle become infected with BLV, they remain infected for life and generate a 
continuous antibody response (Monti et al., 2007; Kobayashi et al., 2010). Clinical signs 
of the disease are not displayed by most infected cattle. Persistent lymphocytosis (PL) 
will occur in approximately 30% of infected cattle and fewer than 5% will eventually 
develop malignant lymphoma (Radostits et al., 2006). 
The prevalence of BLV infection in North America has been high and appears to 
have a rising trend (Bartlett et al., 2014; Chapter 2). For instance, in the Maritime region 
of Canada, herd-level prevalence of BLV infection from 70% in 1998 (VanLeeuwen et 
al., 2001) reached to over 90% in 2013 (Chapter 5). In the United States, as a part of the 
2007 national dairy study (APHIS-USDA report, 2008), 83.9% of the tested herds were 
found to be positive. 
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Measured at the herd level, the direct production losses from EBL in the Canadian 
Maritimes were conservatively estimated at $806 per year in an average 50-cow herd 
(Chi et al., 2002). This did not include costs associated with lost sales of genetically 
superior purebred cattle which are likely more substantial than the direct production 
impacts. In another study, economic loss per case of lymphoma was estimated to be $412 
(Rhodes et al., 2003). With respect to the economic impacts of BLV infection, the most 
significant losses attributed to the disease are: premature culling, death, and 
condemnation of carcasses at slaughter due to lymphoma, production loss, lower 
reproductive efficiency, impaired immune function, as well as trade restrictions imposed 
on infected cattle and their products (Sandev et al., 2000; Bartlett et al., 2014). However, 
reports on production and longevity effects of subclinical BLV in dairy cattle have been 
quite controversial in the literature. A number of studies could not demonstrate any 
statistically significant association between BLV infection and milk production in dairy 
cows and herds (Landston et al., 1978; Huber et al., 1981; Brenner et al., 1989; Da et al., 
1993; Tiwari et al., 2007; Sorge et al., 2011). In contrast, detrimental effects of BLV 
infection on production have been documented by others (Emanuelson et al., 1992; 
Sargeant et al., 1997; D'Angelino et al., 1998; Ott et al., 2003; Erskine et al., 2012). A 
few studies failed to find any statistically significant association between BLV infection 
and the survival of dairy cows (Huber et al., 1981; Tiwari et al., 2005). On the other 
hand, others have reported negative effects of BLV infection on the longevity of dairy 
cows (Pollari et al., 1992; Emanuelson et al., 1992; Bartlett et al., 2013). Moreover, the 
majority of the preceding studies were not able to provide rigorous evidence for 
establishing strong associations between BLV infection and production measures (or 
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longevity) of dairy cows. Some of the likely reasons for obtaining such inconsistent 
findings were: 1) the cross-sectional nature of these studies; 2) limited numbers of study 
cows or herds; 3) in some studies, poor control for potential confounders and application 
of unsuitable statistical analyses; and 4) the use of only production data in the lactations 
in which BLV testing was performed (therefore, not accounting for potential 
seroconversions and progression of the infection pathology). In addition, there has not 
been any study investigating the lifetime impacts of BLV infection, which could 
economically be more relevant with regards to the chronic nature and gradual progression 
of the infection. Therefore, this historical cohort study was conducted to determine the 
effects of BLV infection on 1) lifetime milk production, and 2) longevity of dairy cows in 
Canada. 
3.3 Materials and methods 
In order to assess the lifetime effects of BLV infection on cow longevity and milk 
production, the following steps were taken: 1) generating a master data set by merging 
available BLV test results (from a previous study) with longitudinal lifetime production 
data for the study cows; 2) defining a pool of eligible cows for selecting two comparable 
cohorts of cows (negative and positive to BLV, in a historical cohort setting); and 3) 
longitudinally evaluating the two cohorts of cows with respect to the longevity and milk 
production measures using multilevel regression analyses. The following subsections 
elaborate on the details of the 3 steps, respectively. 
3.3.1 Data collection and management 
The master data set used in this study was generated via combining two data sets, 
the historic BLV test results and the longitudinal production data. The BLV test results 
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were extracted from the Canada-wide surveys of production limiting diseases (Chapter 2) 
that took place between 1998 and 2003 on randomly selected dairy farms in 8 (out of 10) 
provinces of Canada (i.e. source population), including Prince Edward Island (PE), New 
Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), 
Saskatchewan (SK), and Alberta (AB). One of the objectives of that project was to obtain 
estimates for the prevalence of infection with BLV in all participant provinces. Herd and 
animal selections in the surveys were based on a stratified two-stage random sampling 
procedure. From every randomly selected herd (n = 364), a median of 30 cows (range: 9–
45) at different lactations were randomly selected for blood collection. The blood 
samples were tested for BLV antibodies by a commercial serum ELISA (IDEXX 
Corporation, Westbrook, ME, USA; sensitivity = 0.985 and specificity = 0.999). A cow 
was considered to be infected with BLV if the serum-to-positive ratio was ≥ 0.5, as 
recommended by the manufacturer of the test kit. Every herd with at least one infected 
cow was defined as being positive (VanLeeuwen et al., 2001). Complete details on the 
surveys, including sample size calculation, sample collection, and laboratory procedures 
have been published elsewhere (Tiwari et al., 2009; Chapter 2). 
In 2013, based on the available unique identification numbers for all participant 
herds and cows in the former broad surveys, production data (including 305-day milk 
yield (kg), 305-day fat and protein contents of milk (kg), days-in-milk (DIM), average 
somatic cell count (SCC)) for all lactations of a cow during her lifetime was extracted 
from the Canadian dairy herd improvement (DHI) database and combined with the BLV 
test results. All of the cows had been culled or died by the onset of the present study. 
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3.3.2 Study design 
The eligible pool of cows for inclusion in this historical cohort study (i.e. 
sampling frame) consisted of Holstein cows (96% of all cows - to eliminate breed as a 
potential confounder) with complete longitudinal data for lactation measurements (from 
their first lactation to their culling point, with no missing observations; 90% of all 
Holsteins). From this pool, two cohorts of cows (negative and positive to BLV) were 
selected as follows: 
 Positive cohort: cows that tested positive to BLV in their first lactation. Thus, this 
group of cows was considered infected for all of their productive life. 
 Negative cohort: cows that tested negative to BLV in their second or later lactations 
(i.e., disregarding the first lactation test-negative cows). Therefore, this group of cows 
was considered negative from birth to at least the beginning of their third lactation. 
Due to the definition of the negative cohort, only cows with 2 lactations or more 
were included in the study. The reason for applying the outlined inclusion criteria was to 
reduce two major potential sources of bias in establishing the associations of interest in 
the statistical analyses (see section 3.5 for the complete details). 
3.3.3 Statistical analyses 
All of the statistical analyses were carried out in Stata 14 (StataCorp, College 
Station, TX, USA). 
3.3.3.1 Longevity effects 
To assess the effect of infection with BLV (exposure variable, X) on the longevity 
of study cows, the total number of lactations for each cow was used as a measure of 
longevity (Y: lifetime lactations). According to a theoretical causal web (Figure 3.1), 
available variables in the data set, which could potentially have played a role as 
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confounders regarding the association of interest, were incorporated in the modeling 
process (clustering effects of herds and provinces). Within-herd prevalence of BLV was 
included in the modeling because of its interpretation as a contextual effect. 
Hypothesized intervening variables (such as SCC, 305-day milk, fat, and protein) were 
excluded from the modeling.  
To provide a visual representation for the overall impact of BLV infection on 
longevity of the study cows, a Kaplan-Meier survival plot was generated. Because the 
outcome of interest was inherently discrete, a discrete-time survival analysis (Dohoo et 
al., 2009) was performed as follows: 1) the number of life lactations (Y) was set in a 
survival-time framework; 100% failure (i.e. culling or death) occurred in all study cows; 
2) data for each cow was then organized on a one-observation per lactation basis 
(survival-time splitting), with failure occurring in her last lifetime lactation; and 3) 
mixed-effects logistic regression models were built to evaluate the effect of infection with 
BLV on the failure of cows across all lactations. 
3.3.3.2 Lifetime milk production effects 
In order to assess the effect of infection with BLV (X) on lifetime milk production 
of the study cows, the sum of all 305-day milk (kg) produced by each cow during her life 
was calculated to serve as the outcome of interest (Y: lifetime milk). According to a 
theoretical causal web (Figure 3.2), available variables in the data set, which could 
potentially have played a role as confounders regarding the association of interest, were 
utilized in the modeling process. To evaluate the association of interest, mixed-effects 
linear regression models were built, incorporating study herds and provinces as random 
effects. Longevity was included in the models in order to estimate the direct effect of 
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BLV on the life milk production, also in order to avoid multimodal residual distributions. 
Hypothesized intervening variables (such as SCC, 305-day milk, fat, and protein) were 
excluded from the models.  
3.4 Results 
Overall, the master data set consisted of 45,704 lactations for 10,670 cows (with 
one BLV test result per cow) from 364 herds in 8 provinces of Canada. 
Of 10,670 tested cows in the master dataset, 31.7% (n = 3390) were positive to 
BLV-antibodies in the ELISA test. Table 3.1 presents the frequency of tested herds and 
cows in the master data set (source population) and the cohort study by province. Overall, 
4052 cows (with 2-13 life lactations) from 348 herds (with an average of 11.6 cows per 
herd- range: 1-29) met the eligibility criteria and were enrolled in the historical cohort 
study. The two cohorts of negative and positive to BLV included 2194 and 1858 cows, 
respectively (45.8% positive). Table 3.2 presents a descriptive summary of the variables 
investigated in the study. 
3.4.1 Longevity effects 
Figure 3.3 depicts the Kaplan-Meier survival plot for longevity (lifetime 
lactations) of the two cohorts of cows. According to the graph, BLV-positive cows show 
a clear shorter longevity as compared with BLV-negative cows. All positive cows were 
culled/died prior to their tenth life lactation; only 19 (1%) and 2 (0.1%) positive cows 
lived to their 8
th
 and 9
th
 lactations, respectively. In the negative cohort, 13.5% of the cows 
experienced lactations > 7 (8 to 13). Hence, in order to make meaningful comparisons 
between the two cohorts, the final logistic model was confined to the life lactations < 8 
(by censoring lactations > 7 in the study cows- this period is also consistent with the 
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economic life of dairy cows). The output for the final mixed-effects logistic model is 
presented in Table 3.3. This model included 14,243 lactations, from the 4052 cows. 
Random effects of province explained only 3.5% of the total unexplained 
variation in the final model, when approximating the lowest-level variance by 3.29 
(Dohoo et al., 2009). Variability among herds explained 7.4% of the total variation, 
suggesting altogether minor clustering effects for cows within the herds and provinces 
with regard to the longevity. Estimated within-herd prevalence of BLV was positively 
associated with the longevity of the study cows (P = 0.002), indicating that cows from 
highly infected herds tended to have shorter lives compared to the cows from low-
prevalence herds (that is a contextual effect of BLV infection). 
In the final model (Table 3.3), the interaction term between time (i.e. lactation 
number) and BLV status was highly significant (P < 0.001), indicating that the effect of 
BLV infection on the odds of failure (culling or death) was dependent on the lactation 
under consideration. Therefore, an interaction plot was produced to illustrate the 
relationship between the predicted probability of culling/death and longevity by BLV 
status for the study cows, while the within-herd prevalence was held constant at its mean 
value of 0.36 (Figure 3.4). From the graph, BLV-positive cows had constantly greater 
probability of being culled (or dying) than BLV-negative cows over the course of the 
comparison (P < 0.001 for all lactations). As the cows lived longer, the difference in the 
probability of culling between the two cohorts gradually increased (with an exception in 
the 5
th
 life lactation), from 13.4% at the second lactation to 26.2% at the seventh 
lactation. On the other hand, the relative impact of BLV in terms of the odds-ratio was 
largest in the second lactation (Table 3.3).  
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3.4.2 Lifetime milk production effects 
Similar to the longevity analyses, in order to make meaningful comparisons 
between the two cohorts of cows, and to be consistent with the economic life of dairy 
cows, lifetime milk production for cows with 2-7 lactations was the outcome in the 
analysis. 
To satisfy the assumptions of mixed-effects linear models, lifetime milk 
production was square-root transformed and used as the outcome of interest. Within-herd 
prevalence of BLV (the contextual effect) did not show any significant effects on the 
outcome; therefore, it was not included in the final model (Table 3.4). The interaction 
term between BLV-status and longevity of the cows was highly significant (P < 0.001), 
indicating that lifetime effects of BLV infection on the total milk production was 
dependent on the lactation number in which the study cows were culled/died. This 
interaction is illustrated in Figure 3.5. As depicted, BLV-positive cows with 2 and 3 
lactations (i.e. with short longevity) showed significantly lower life milk productions: 
(after back-transformation to original scale) -2554 kg (95% CI: -3609 to -1500) and -
1171 kg (95% CI: -2051 to -292), respectively, as compared with their negative 
counterparts with 2 and 3 lactations. As the cows lived longer (> 3 lactations), the 
differences in life milk production between the two cohorts were no longer substantial, 
nor statistically significant. 
Despite the fact that the random effect of province was statistically significant in 
the final model, it only explained 5.8% of the total unexplained variation in the model. In 
contrast, the random effect of herds explained a considerable proportion of the total 
variation in the model (24.5%). Over 69% of the variation in the lifetime milk production 
was due to variability among the individual cows. 
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3.5 Discussion 
This was the first time that the lifetime impacts of BLV infection were 
investigated on a broad scale. Our study provided more rigorous evidence for direct 
effects of BLV infection on longevity and milk production as compared with the historic 
studies, because of the following advantages: 1) wide study area (herds and cows from 
across Canada); 2) a large number of participants (4052 cows from 348 herds); 3) study 
design (historical cohort), which is the strongest type among observational studies 
towards establishing causal associations (Dohoo et al., 2009); and 4) including data from 
all life lactations of the study cows which can reflect the gradual nature and impacts of 
BLV infection. 
Previous studies on production and longevity effects of BLV infection (mentioned 
in the introduction section) were cross-sectional and incorporated production data 
restricted to the lactations in which BLV-testing was implemented or a few lactations 
afterwards. As a result, their findings could have been influenced by two major sources of 
bias: 
1) Positive cows: for most of the BLV-positive cows, it was not clear when exactly 
they became infected. For instance, assume a cow that was diagnosed positive by a test 
conducted in her late life lactations (e.g. > 4); this cow could have become infected at any 
time prior to the testing date, while it was simply regarded as BLV-positive in the 
analyses. If the cow became infected early in life (i.e. far from the testing date), 
production effects of the infection could be well reflected by the later lactations. 
Conversely, if this cow became infected sometime closer to the testing date (e.g. during 
the fourth lactation or later), the concurrent production data might not truly represent the 
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impacts of BLV infection because such effects gradually develop over time. In particular, 
the adverse effects due to developing PL and/or lymphoma have a strong association with 
reduced production and survival of infected cows (Pollari et al., 1992; Da et al., 1993; 
Radostits et al., 2006). To address this possible source of bias, we restricted our positive 
cohort to the cows, which were tested during their first lactation only. Hence, these cows 
certainly became test-positive early in their life (before or during the first lactation), and 
their lifetime effects could reflect the true impacts of BLV infection more sensibly during 
the subsequent lactations. 
2) Negative cows: BLV-negative cows could have become infected (seroconverted) 
at any time after the lactation in which BLV testing was done and therefore introduced a 
partial misclassification bias. This issue could particularly be concerning when negative 
cows were tested early in life. In this case, the potential BLV impacts would gradually 
develop during the consequent life lactations and confound the results. In our study, we 
restricted the negative cohort to cows that were tested negative at least in their second 
lactations. Therefore, we should not expect substantial bias due to likely seroconversions 
in an appreciable fraction of negative cows, because: 1) the probability of developing 
new infections (i.e. incidence rate, not prevalence) is expected to gradually decline after 
4-5 years of age (Radostits et al., 2006; Kale et al., 2007); 2) 55.5 % of our study cows in 
the negative cohort had been tested during their third or later lactations (thus the 
likelihood of seroconversion and its later life impacts would be even less important); and 
3) even if some new infections occurred following the second lactation (> 4 years of age) 
in a fraction of negative cows, there should not be prominent effects on the total 
(lifetime) production because of the gradual progress and chronic nature of BLV 
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infection. We did not further limit our negative cohort to the cows tested in their third or 
greater lactations due to loss of many observations (25%) in the study. However, to 
address any potential concerns, a sensitivity analysis was done in which the negative 
cohort was restricted to cows that were exclusively tested negative in their third or later 
lactations; our main conclusions were unaffected (results not shown).  
To entirely remove the outlined sources of bias, repeated testing for BLV (to 
detect any new occurrence of the infection), along with the differential blood cell count 
(to record any possible change/progress in the course of the infection; e.g. advancing to 
PL status) during the lifespan of cows would be required. However, additional testing 
would add substantial practical and cost implications in large field studies such as ours. 
Pollari et al. (1992) and Da et al. (1993) were the only researchers who implemented 
repeated testing for BLV and differential blood cell counts over 3- and 6-year periods 
(respectively) to record potential seroconversions, and progress of the infection. 
However, their studies were confined to one dairy herd with limited number of cows. 
Therefore, the generalizability of their findings could be questionable. They reported that 
the adverse effects of BLV infection were primarily limited to PL cows, which were 
culled earlier and had reduced milk during their culling lactations. 
With respect to the natural history of BLV infection, evaluating its impacts on 
production parameters in the long-term could be much more enlightening than during 
only one (concurrent) or a few lactations after testing. Approximately, 30% of the 
infected cattle develop PL during their life (Schwartz and Levy, 1994). Persistent 
lymphocytosis without clinical signs can occur earlier in life, but rarely before 2 years of 
age. Many cows remain in the preclinical stage for years, often for their complete 
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productive lifetime without any apparent reduction in performance, but lymphoma 
eventually appears in a proportion of these cows (in 5% of the infected cows). 
Lymphoma is rarely seen in animals less than 2 years of age and is most common during 
lactations 2 to 6 (Radostits et al., 2006; Smith, 2009). This period of high risk, during 
which observing the potential impacts of BLV infection on the performance would be 
expected, was well covered in the present study. 
3.5.1 Longevity effects 
Overall, infected cows lived significantly shorter than their negative counterparts 
in our study, suggesting that infection with BLV could in fact be one of the causes of 
premature culling (or death) in any age group of cows. This effect was not substantially 
influenced by the herd of origin (e.g. by herd-level management decisions) because 
approximately 90% of the unexplained variation in the likelihood of culling was 
explained by the individual cow variability. 
As the study cows aged, the probability of culling remained significantly higher in 
the positive cohort compared to the negative cohort. This is in agreement with the gradual 
progress of the infection over time; for instance, because of increasing the number of 
cows with PL and lymphoma which could lead to a higher culling rate in older infected 
cows. In this regard, adverse consequences of the infection, such as abnormal immune 
function and reproductive performance, could play an important role in vulnerability to 
other infections such as mastitis (Vanleeuwen et al., 2010; Frie and Coussens, 2015). In a 
large Swedish study, it was suggested that the risk for other infectious diseases of dairy 
cattle was greater in BLV-positive herds compared to BLV-negative herds (Emanuelson 
et al., 1992). In the Canadian dairy industry, reproductive disorders, mastitis, and feet and 
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leg problems have usually been the top three causes for culling and replacements (Canada 
dairy-info, 2015). Considering its high prevalence in Canada, infection with BLV 
(particularly in the long-term) could act as a confounder for the effects of the mentioned 
disorders on culling rate. Culling cows before they reach their maximum genetic potential 
for production and reproduction is one the most important sources of economic loss in all 
dairy herds (Chi et al., 2002). 
Thurmond et al. (1985) reported longer survival (beyond 3.5 years of age) 
among antibody-negative cows than among positive cows in a dairy herd. Erskine et al. 
(2012) found a herd-level negative association between cow age, estimated as the 
percentage of the herd in the third or greater lactations, and BLV prevalence. Bartlett et 
al. (2013) investigated the longevity of BLV infected cows in 112 dairy herds from 
Michigan and showed that infected cows were 23% more likely to be culled or die 
compared with their negative counterparts. However, they only followed the cows for an 
average of 597 days after BLV testing and only 48.3% of the cows were culled by the end 
of study. In contrast, a few studies failed to find any statistically significant association 
between BLV infection and the survival of dairy cows, although they did not look at 
lifetime longevity (Huber et al., 1981; Tiwari et al., 2005). An additional caution should 
be taken when interpreting culling results if the owners received the BLV test-positive 
results – cows could have been culled just because they were BLV test-positive without 
any clinical or subclinical manifestation of the infection, especially if a farmer had a 
small number of test-positive cows and eradication was the farm goal. This could result 
in some overestimation in the significance of the association of interest (i.e. bias away 
from the null); however, the magnitude of this potential bias is believed to be low. 
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3.5.2 Milk production effects 
Including the interaction term between BLV infection status and lifetime 
lactations in the analysis allowed for comparison between the two cohorts of cows at each 
age group. The quantity of loss in milk production for BLV-positive cows that were 
culled in their second and third lactations was substantial. One of the possible reasons for 
this finding could be adverse impacts of advanced BLV infection (e.g. PL stage) on the 
milk production, or indirectly through compromised immune function (Kabeya et al., 
2001; Frie and Coussens, 2015). Hence, the affected cows were presumably removed 
from the herds due to insufficient milk production or other reasons in early lactations. In 
addition, it could be assumed that the positive cows that lived longer were mostly among 
those that did not develop advanced stages of the infection (approximately 70% of 
infected cows) and/or were genetically superior cows with high potential for milk 
production. Overall, it appears that subclinical BLV infection did not have a prominent 
effect on life milk production for the cows that lived their expected economic life (> 5 
years of age). The impact of BLV infection on lifetime milk production was clustered 
within the herds, indicating the actual differences varied among these herds with regards 
to several factors, which could include genetic value/merit of their cows, nutrition, and 
other management practices. 
If one were to consider a partial budget for total BLV economic impact, the 
culling of poor milk-producing cows transfers the cost of poor production from the milk 
production component to the culling component. Therefore, overall survival of BLV-
infected dairy cattle may be a more comprehensive measure of the impact of BLV on a 
dairy herd in that it includes cow removal from the herd for a variety of reasons that may 
result from hypothesized BLV-altered immune function (Bartlett et al., 2013).  
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Sorge et al. (2011) could not demonstrate any significant association between 
BLV infection and milk production of 19,785 cows from 258 herds in Ontario and 
western Canada. They only evaluated the test-day lactations and combined the suspicious 
samples with the negative results, which might have caused the non-significant effect. 
There have also been other studies which could not reveal any significant association 
between BLV infection and production measures (Brenner et al., 1989; Jacobs et al., 
1991; Kale et al., 2007). However, none of these studies looked at lifetime parameters. 
Erskine et al. (2012) reported that each 0.1 increase in the proportion of positive 
cattle in 104 Michigan dairy herds was significantly associated with a 115 kg decrease in 
12-month rolling herd average milk yield per cow. Ott et al. (2003), in a large US study, 
showed that herds with seropositive cows produced 218 kg per cow less milk compared 
with negative herds. Da et al. (1993) demonstrated that positive herds produced 3% less 
milk per cow. However, it is notable that the herd-level evaluations are prone to 
“ecological fallacy”; that is, the results may not be generalizable to the individual cows – 
some infected cows may be producing more milk than non-infected cows in a positive 
herd (Jacobs et al., 1991). 
In a study limited to one 219-cow dairy herd in the US, it was shown that milk 
production during the testing lactation in seropositive cows was lower than that in their 
negative herd mates, after adjustment for genetic potential for milk production in the 
study cows (Wu et al., 1989). With respect to the importance of the discovered links 
between genetic composition of cows and vulnerability to BLV infection and its progress 
rate (Jubb et al., 1993; Fenner et al., 2011; Frie and Coussens, 2015), controlling for 
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production merits of cows in the analyses could be of particular interest. We, however, 
did not have access to this information. 
Another limitation in most BLV-focused studies (including the present study) is 
that no information on progress and course of the infection is available. As discussed, 
30% of the infected cows will develop PL at some point in their life, which could 
prominently affect their production (Pollari et al., 1992; Da et al., 1993). Despite being 
costly and sometimes impractical in field conditions, repeated testing for BLV and 
lymphocyte counts over the economic life of cows could provide valuable insight into the 
definitive impacts of the infection. With the high prevalence of BLV infection across 
Canada (see Chapter 5 for a prevalence update) and its outlined negative economic 
impacts, pursuing broad-based, efficient control programs in Canada is imperative. 
3.5.3 Conclusions 
With the chronic nature and gradual progress of BLV infection, evaluating BLV’s 
economic impacts over the lifetime of dairy cows is very informative. The design of the 
present study (historical cohort) was well suited for describing the potential causal 
associations between BLV infection and the corresponding lifetime production and 
longevity effects. Seropositive cows had consistently shorter lifespans compared with 
their negative counterparts, suggesting that the infection could be one of the main causes 
of premature culling (or death) at any age groups of cows. Seropositive cows that were 
culled at early lactations (second and third) exhibited substantially lower milk production 
than seronegative cows. However, the lifetime milk production in the two cohorts among 
long-living cows (> 3 lactations) did not show any significant difference. Overall, with 
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the high prevalence of BLV infection across Canada and its detrimental economic 
impacts, pursuing broad-based control programs is highly recommended. 
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Table 3.1. Frequency distribution of the tested herds and cows for bovine leukemia virus 
antibodies in source (M) and study (S) populations, from 8 provinces of Canada. 
Province No. of  
tested herds 
No. of  
tested cows 
No. of  
positive cows 
Proportion of  
positive cows (%)
a 
 M
b 
S
c 
M S M S M S 
Prince Edward Island 30 29 805 340 150 42 18.6 12.3 
New Brunswick 30 26 791 251 106 23 13.4 9.1 
Nova Scotia 30 29 785 327 253 71 32.2 21.7 
Quebec 93 87 2285 637 632 349 27.6 54.7 
Ontario 31 31 800 281 260 134 32.5 47.6 
Manitoba 40 37 1109 563 643 511 57.9 90.7 
Saskatchewan 44 44 1641 692 585 249 35.6 35.9 
Alberta 66 65 2454 961 761 479 31.0 49.8 
Total 364 348 10670 4052 3390 1858 31.7 45.8 
a 
Number of positive cows/Number of tested cows 
b
 M: in master data set (source population) 
c
 S: in study population 
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Table 3.2. Summary statistics for the variables used in the study on 4052 dairy cows. 
Variable
a
  Brief description   Mean SD Min Median  Max 
Longevity Total life lactations: Y1
b 
4.65 1.87 2 4 13 
Milk (kg)   Total life 305-day milk yield:Y2
c
  38629.23 18940.27 3177 36273 141892 
WHP
d 
(%) Within-herd prevalence 36.23 30.71 0 33.33 100 
Fat (kg) Average of all 305-day fat 328.52 61.05 129 328.25 611.50 
Protein (kg) Average of all 305-day protein 292.88 50.15 100 294.50 521 
Ln-SCC
e 
Average of  all ln-SCC 3.10 1.28 0.10 2.93 8.50 
a “
Fat, Protein, and Ln-SCC” were originally lactation-level variables which have been 
averaged at the cow level. 
b 
The outcome of interest for evaluating the effect of bovine leukemia virus infection on 
longevity (Y1). 
c 
The outcome of interest for evaluating the effect of bovine leukemia virus infection on 
lifetime milk production (Y2).  
d 
Estimates of within-herd prevalence of infection with bovine leukemia virus in the study 
herds. 
e 
Average linear score of somatic cell counts was only available for 3654 cows (398 were 
missing). 
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Table 3.3. Results of the final mixed-effects logistic model, evaluating the lifetime effects 
of infection with bovine leukemia virus (BLV) on the log-odds of culling/death for the 
4052 study cows. 
Variable Coefficient SE  95% CI  Odds-ratio 
Fixed effects        
Life lactation         
2 - -  - -  - 
3 1.24 0.12  1.01 1.48  3.47 
4 1.79 0.17  1.57 2.02  6.02 
5 2.37 0.12  2.14 2.59  10.68 
6 2.81 0.12  2.57 3.06  16.71 
7 3.03 0.13  2.77 3.29  20.76 
BLV * Life lactation 
a 
       
2 1.52 0.12  1.27 1.76  4.57 
3 1.05 0.09  0.86 1.23  2.86 
4 1.02 0.09  0.84 1.21  2.79 
5 0.83 0.11  0.61 1.05  2.29 
6 0.89 0.15  0.59 1.19  2.44 
7 1.23 0.27  0.71 1.76  3.44 
Within-herd prevalence  0.31 0.10  0.11 0.51  1.36 
Constant -3.23 0.11  -3.44 -3.02  - 
Random effect variances        
Province 0.13 0.11  0.02 0.64  - 
Herd 0.27 0.07  0.17 0.45  - 
a
 Interaction term between BLV infection status and number of life lactations.  
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Table 3.4. Results of the final mixed-effects linear model, evaluating the lifetime effects 
of infection with bovine leukemia virus (BLV) on the square-root of total life milk 
production (kg) for the 4052 study cows.   
Variable  Coefficient SE  95% CI 
Fixed effects       
Life lactation       
2 - -  - - 
3 26.49 2.14  22.31 30.68 
4 52.05 2.08  47.98 56.13 
5 74.46 2.06  70.43 78.49 
6 98.66 2.09  94.56 102.77 
7 121.03 2.04  117.02 125.04 
BLV * Life lactation 
a 
     
2 -10.58 2.17  -14.84 -6.32 
3 -3.89 1.48  -6.80 -0.98 
4 0.93 1.43  -1.88 3.74 
5 1.11 1.52  -1.86 4.08 
6 1.72 1.83  -1.87 5.31 
7 0.31 2.24  -4.08 4.70 
Constant 125.99 2.71  120.68 131.30 
Random effect variances      
Province 27.74 17.52  8.04 95.66 
Herd 116.14 11.96  94.91 142.12 
Cow 331.39 7.71  316.61 346.85 
a 
Interaction term between BLV infection status and number of life lactations.   
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Figure 3.1. A theoretical causal web, illustrating relationships among the potential 
confounding or intervening variables with respect to the association of interest (dashed 
arrow) between bovine leukemia virus (BLV) infection (exposure) and longevity 
(Lifetime lactations). Random effects of “province” and “herd” clustering the study cows 
have been included. Within-herd prevalence of BLV infection (contextual effect), 
average lifetime 305-day milk, fat, protein, and average linear score of somatic cell count 
(SCC) at the cow level (as a block) were considered as well. 
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Figure 3.2. A theoretical causal web, illustrating relationships among the potential 
confounding or intervening variables with respect to the association of interest (dashed 
arrow) between bovine leukemia virus (BLV) infection (exposure) and lifetime 305-day 
milk production (Lifetime milk). Random effects of “province” and “herd” clustering the 
study cows have been included. Within-herd prevalence of BLV infection (contextual 
effect); the total number of life lactations (longevity); as well as average lifetime 305-day 
fat, protein, and average linear score of somatic cell count (SCC) at the cow level (as a 
block) were considered. 
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Figure 3.3. Kaplan-Meier survival plot for 4052 study cows, by the two cohorts of test-
negative and test-positive cows for bovine leukemia virus (BLV) infection. 
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Figure 3.4. Interaction plot illustrating the relationship between the predicted probability 
of culling/death (Y-axis) and longevity (lifetime lactations; X-axis) by bovine leukemia 
virus (BLV) infection status, along with the corresponding 95% confidence intervals 
(spikes) for 4052 study cows. 
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Figure 3.5. Interaction plot illustrating the relationship between predicted lifetime milk 
production (after back-transformation to original scale; Y-axis) and longevity (lifetime 
lactations; X-axis) by bovine leukemia virus (BLV) infection status, along with the 
corresponding 95% confidence intervals (spikes) for 4052 study cows. 
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CHAPTER 4 
 
 
 
CARRYOVER OF BOVINE LEUKEMIA VIRUS ANTIBODIES IN 
SAMPLES FROM SHARED MILK METERS 
 
 
 
 
 
 
 
This chapter has been published in the Journal of Dairy Science (without substantive 
change): 
 
“Nekouei, O., J. Sanchez and G. Keefe. 2015. Carryover of bovine leukemia virus 
antibodies in samples from shared milk meters. J. Dairy Sci. 98: 5274-5279.” 
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4.1 Abstract  
Screening for infectious diseases of cattle using milk from the dairy herd 
improvement (DHI) sampling process is very convenient. However, when samples from 
shared milk meters are used, carryover of antibodies or other diagnostic targets can 
complicate the interpretation of the diagnostic test results for diseases, including bovine 
leukosis. The objectives of this chapter were: 1) to assess the potential for carryover of 
antibodies against bovine leukemia virus (BLV) in milk samples obtained from shared 
meters, and 2) to determine if adjustment of the diagnostic test cut-off value would 
improve the test characteristics for meter-collected milk ELISA results.  
Eight dairy farms were randomly selected from herds with a wide range of BLV 
prevalence levels in Prince Edward Island (PE), Canada. Within each chosen farm, two to 
four milk meters were randomly selected. During the routine procedures of DHI 
sampling, two simultaneous milk samples, one hand-collected at the beginning of milking 
(after udder preparation), and the other from the corresponding milk meter were taken 
from all lactating cows (n = 236) that were milked at the selected meters (n = 26). The 
sequence of cows using each meter was recorded. All samples were tested for BLV 
antibodies using a commercial indirect ELISA. Antibody carryover potential was 
assessed in meter-collected samples, which were preceded by other cows using the same 
meters. Applying the hand-collected sample results as the reference standard, a new cut-
off was defined for the meter-collected samples to optimize the test characteristics.  
At the standard cut-off value of the diagnostic test, 110 (46.6%) of the hand-
collected, and 136 (57.6%) of the meter-collected samples were positive. For low-titer 
cows (e.g. true negatives), the likelihood of antibody carryover significantly increased as 
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the titer of preceding cows increased, while this change was not substantial for high-titer 
cows. The odds of obtaining false diagnoses in meter-positive samples became larger 
with increase in the titer of preceding cows. A suspicious category for meter ELISA 
results was defined, and a retest was recommended for the cows falling into this category. 
This strategy effectively assisted in reducing the number of consequent false positive 
results. When DHI-collected samples are used, carryover can affect the interpretation of 
dichotomous test results, and may require adjustment of assay cut-off values. 
4.2 Introduction 
Enzootic bovine leukosis (EBL) is an economically important disease of dairy 
cattle caused by bovine leukemia virus (BLV). In North America, prevalence of the 
infection has been high and appears to have a rising trend (Samagh and Kellar, 1982; 
Richardson and Macaulay, 1992; Sargeant et al., 1997; VanLeeuwen et al., 2001; 
VanLeeuwen et al., 2005; VanLeeuwen et al., 2006; Bartlett et al., 2014). For instance, in 
Prince Edward Island, Canada, herd-level prevalence of BLV was 49.2% in 1989 
(Richardson and Macaulay, 1992), increased to 63.3% in 1998 (VanLeeuwen et al., 
2001), and is currently at 90% based on a survey of bulk tank milk in all dairy herds in 
the province completed in 2013 (Chapter 5). However, no broad-based national program 
for controlling EBL in Canada and the United States has been implemented. 
A number of studies have recently been conducted to estimate the prevalence of 
BLV infection and define cost-effective screening tools to be applied in control 
programs. Monitoring meter-collected milk samples, obtained from the dairy herd 
improvement (DHI) process has become one of the standard and economically efficient 
procedures for screening for important infectious diseases in dairy cattle, such as bovine 
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viral diarrhea, Johne’s disease, and EBL (Attalla et al., 2010; Sorge et al., 2011). Among 
the available commercial tests for detection of antibodies against BLV, milk ELISA is a 
desirable method in large-scale herd surveillance, because milk sampling during the DHI 
process is much more convenient and cost-effective than serum collection (Erskine et al., 
2012). 
With respect to sequential milk samples, carryover denotes the risk of inclusion of 
some residual milk from the previous cows in the subsequent milk samples (Ordolff, 
1997; Lovendahl and Bjerring, 2006). With increasing utilization of DHI diagnostic 
services on meter-collected samples, there is a legitimate concern regarding carryover or 
cross-contamination of milk samples from shared milking equipment. 
The objectives of this study were: 1) to assess the potential for carryover of BLV 
antibodies in milk samples obtained from shared meters, and 2) to determine if 
adjustment of the diagnostic test cut-off value would improve the test characteristics for 
meter-collected milk ELISA results. 
4.3 Materials and methods 
4.3.1 Sample collection 
Based on a companion study using bulk tank milk samples from all dairy farms in 
Prince Edward Island (PE), Canada, all DHI-participant farms were assigned into 5 
separate categories of BLV infection level: category 1) assumed uninfected, 2) low 
prevalence, 3) medium prevalence, 4) high prevalence, and 5) very high prevalence farms 
(Chapter 5). In July 2013, two farms were randomly selected from each of the categories 
2 to 5 (8 farms in total). Within each selected farm, two to four milk meters were 
randomly selected, proportional to the lactating herd size (Table 4.1). During one round 
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of the routine DHI sampling procedure, two simultaneous milk samples (30 ml each), one 
hand-collected at the beginning of milking (after udder preparation), and the other from 
the corresponding milk meter, were taken from all lactating cows (n = 236) that were 
milked at the selected meters (n = 26). The sequence of the cows milked using each meter 
was precisely recorded by the project personnel. 
4.3.2 Laboratory testing 
Meter-collected samples were submitted to the Maritime Quality Milk (MQM) 
laboratory located at the Atlantic Veterinary College, University of Prince Edward Island, 
in Charlottetown, after undergoing the standard quality and components analyses in a 
local DHI laboratory (PEI Analytical Laboratory, Charlottetown, PE). Hand-collected 
samples were directly submitted to the MQM laboratory. All samples were tested for BLV 
antibodies using a commercial indirect ELISA kit (SVANOVIR BLV gp51-Ab, Svanova, 
Uppsala, Sweden). The test results were reported as percent positivity (PP) values [PP = 
(ODcorrected sample/ODcorrected positive control) × 100, where OD is optical density], and 
the recommended cut-off value of the kit for individual cow milk samples was 10. 
4.3.3 Statistical analyses 
All of the statistical analyses were conducted in Stata 13.1 (StataCorp, College 
Station, Texas. USA). 
4.3.3.1 Agreement 
To evaluate the overall agreement between hand (PPhand) and meter (PPmeter) test 
results, a scatter diagram was produced and the concordance correlation coefficient was 
calculated. In addition, the overall agreement of the dichotomized results (at the 
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recommended cut-off of 10) from the two types of samples was explored using 
McNemar’s Chi-square test and Cohen’s kappa coefficient (Dohoo et al., 2009). 
4.3.3.2 Carryover effects  
In order to determine the potential carryover effects of BLV antibodies, all cows 
which had been preceded by other cows at the same meters, contributed to building a 
multivariable linear regression model. It was assumed that the difference between meter- 
and hand-collected ELISA values for each cow (Y = PPmeter – PPhand) was a function of 
hand value for the cow (PPhand; X1), meter value from the preceding cow (PPmeter-1; X2), 
and their interaction term (X1X2). The final model was as follows:  
Y = β0 + β1X1 + β2X2 + β3X1X2 + ε 
In the equation, β0 is the intercept; ε is the residuals of the model; and other βs are 
regression coefficients corresponding to the terms defined above; Y represents the 
potential carryover effects. To control for the potential clustering effects of herds, robust 
standard errors were applied to the estimates. 
A one-sample T-test was performed to determine whether the average of the 
difference (Y) values for the cows, which were milked first per meter (first-per-meter 
cows) was significantly different from zero. 
4.3.3.3 Carryover in meter-positive samples 
To specifically explore the impact of carryover on generating extra false positive 
results to BLV infection, all meter-positive cows (PPmeter ≥ 10) that were preceded by 
other cows at the same meters were extracted (n = 133; three missing values). The 
difference between the hand value of each cow (PPhand) and the hand value from the 
previous cow (PPhand-1) using the same meter was then calculated (PPhand – PPhand-1). A 
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logistic regression model was built to determine the impact of this difference, as a 
surrogate for potential carryover, on the odds of obtaining a false positive diagnosis 
(positive in meter, but negative in hand samples), as compared to the odds of a true 
positive diagnosis (positive in both types of the samples). 
4.3.3.4 ELISA cut-points 
Finally, to explore new ELISA cut-off values that would minimize the proportion 
of false positives in the routine application of the test on meter samples, a two-graph 
receiver operating characteristic (ROC) analysis was carried out (Dohoo et al., 2009). 
The optimal adjusted cut-off for meter-collected samples was determined using the 
dichotomized hand-collected results as the reference standard. Based on the original kit 
and the adjusted cut-off values for the meter-collected samples, three categories of 
ELISA results (negative, suspicious, and positive) were defined. 
4.4 Results 
Descriptive data on study herds and samples are presented in Table 4.1. Lactating 
herd size in the study herds ranged from 46 to 126. Between 12 and 48 cows from the 
study herds were sampled for a total of 236 cows (all Holstein). Based on the 
recommended cut-off of the test, 110 cows (46.6%) in the hand-collected samples, and 
136 cows (57.6%) in the meter-collected samples were found to be positive.  
4.4.1 Agreement  
The McNemar’s Chi-square test was highly significant (P < 0.001), suggesting 
that the proportion of positive test results disagreed between the dichotomized hand- and 
meter-collected results. Because the McNemar's test was significant, the Cohen's kappa 
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result is not presented. When examined on a continuous basis, there was a strong 
correlation [concordance correlation coefficient = 0.905 (95% CI: 0.882-0.928)] between 
the two sets of the PP values. This relationship is illustrated in Figure 4.1. 
4.4.2 Carryover effects 
The final linear model (Table 4.2) included 207 cows (25 first-per-meter cows 
and one missing; as well as 3 cows with unavailable previous values). The interaction 
term between PPhand and PPmeter-1 was highly significant (P < 0.001), indicating that the 
behavior of antibody carryover against the preceding cows’ meter titers depended on 
different levels of cows’ hand titers. To clarify this interaction, a graph was produced to 
illustrate changes in Y for the cows versus titer of the preceding cows (PPmeter-1) at three 
different constant levels of PPhand values (Figure 4.2). From the graph, for the cows with 
low levels of BLV antibody titer (e.g. PPhand < 30; including all negatives), predicted 
antibody carryover (Y) increased as the titer of their preceding cows increased. As the 
titer of cows increased (e.g. PPhand > 60), antibody carryover started showing a weaker 
positive association with changes in the titer of previous cows, until it gradually faded 
towards being insignificant. The T-test for the first-per-meter cows resulted in a P-value 
of 0.289, indicating the average of Y values was not significantly different from zero. In 
other words, when there was no possibility for carryover at all, the average of 
measurement differences between hand- and meter-collected values would be minor. 
4.4.3 Carryover in meter-positive samples 
Based on the simple logistic model, the carryover effect in positive samples was 
highly significant (P < 0.001). With each unit (percent positivity) increase in PPhand – 
PPhand-1, the log-odds of getting a false diagnosis decreased by 0.050 (95% CI: 0.031-
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0.067); i.e. preceding by a high titer cow at the same meter, significantly increased the 
odds of false positive results in the subsequent meter-positive samples. 
4.4.4 ELISA cut-points 
Figure 4.3 illustrates the two-graph ROC curve (sensitivity/specificity versus all 
possible cut-off values). According to the graph, the cut-point for optimizing test 
characteristics would be achieved at a PP of approximately 45. If the later cut-off was 
used alone, we would gain a quite higher specificity (from 0.777 to 0.984), while the loss 
in sensitivity would be relatively negligible (from 0.982 to 0.955). Consequently, the 
number of false positive results substantially reduced (from 28/136 to 2/106), whereas the 
impact on the false negatives was relatively small (increased from 2/100 to 6/130). As 
presented in Table 4.3, three categories of the ELISA values were defined as: 1) negative 
(PPmeter < 10); 2) doubtful or suspicious (10 ≤ PPmeter ≤ 45); and 3) positive (PPmeter > 45). 
Thirty samples were located within the suspicious range, and 86.7% (26/30) of those 
were falsely positive (i.e. negative in hand-collected samples), whereas only 1.9% 
(2/106) of the samples within the positive range were falsely positive. 
4.5 Discussion 
In our study, we found a significant carryover when cows with high BLV 
antibody titers preceded low-titer (e.g. true negative) cows at the same meters. For 
instance, based on the interaction plot, if a negative cow was preceded by a positive cow 
with medium-to-high titer (e.g. > 50), adequate levels of carried BLV antibodies could be 
detected and led to a false positive diagnosis. In high prevalence herds, where there is a 
higher chance of meter contamination, and therefore risk of carryover, substantial number 
of non-infected cows may be falsely diagnosed at the published cut-off. Different studies 
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have evaluated the importance of carryover of milk components (e.g. fat, protein, and 
somatic cell count) in samples from automated milking systems (Dill, 1974; Ordolff, 
1997; Friggens and Rasmussen, 2002; Lovendahl and Bjerring, 2006). For conventional 
milking meters, Dill (1974) indicated a significant carryover effect on the milk fat when 
the previous sample was as much as 1% higher or 2% lower in fat than the tested sample. 
Byrem et al (2013) stated that when measuring endogenous milk components such as fat 
and protein, the influence of existing carryover was negligible, but this effect could 
particularly be important on exogenous components (such as antibodies or other 
diagnostic targets). They further suggested that carryover of 3% milk between samples 
could result in detectable levels of antibody in milk in an uninfected cow if preceded by 
an infected cow having milk antibody levels at relatively low levels (Byrem et al., 2013). 
Despite this, we were not able to find any published data on antibody carryover in 
conventional milk meters. 
To account for BLV antibody carryover, we defined three levels of sample results 
for optimizing the performance of the current ELISA test. Samples with PPmeter <10 were 
negative and those > 45 were positive, while samples with 10 ≤ PPmeter ≤ 45 were 
considered a suspicious category. As indicated in Table 4.3, the majority of cows in the 
suspicious range were in fact negative. Hence, if a cow falls within this range, a retest 
should be requested. The retest sample should be a direct hand-collected milk sample or a 
serum sample. Subsequently, the second test result should be interpreted based on the 
original dichotomous cut-off of the kit. Putting this strategy in place, a substantial 
number of false positive diagnoses could efficiently be prevented without loss in 
sensitivity (i.e. no extra false negatives are generated). This gain can economically be 
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significant when test and removal, or test and segregation programs for BLV infection are 
pursued. For herds with medium or high levels of within-herd prevalence, such as many 
dairy farms in North America, management strategies for controlling BLV are preferred 
due to considerable cost (and/or impracticality) of removal and segregation programs 
(Sandev et al., 2000; Bartlett et al., 2014). Therefore, our recommendations could provide 
a more cost-effective screening or monitoring tool for accomplishing the control 
measures. 
Other methods for controlling the carryover effects have also been proposed, such 
as diluting meter milk samples before testing (Walsh et al., 2013). This method could 
potentially cause extra false negative results for low-titer positive samples, and interfere 
with precise measurements on milk components during DHI procedures. A potentially 
useful method for avoiding carryover effects could be recommending rinsing of milk 
meters between cows. This procedure is likely to reduce carryover, but may be difficult to 
consistently adhere to because of time pressures during milking on many dairy farms. 
Despite the challenges identified in this research, DHI-collected samples offer many 
economical and logistic advantages for screening for BLV (or other common pathogens 
in dairy cattle). 
Overall, we had only two (0.8%) false negative results (i.e. negative in meter, but 
positive in hand-collected samples). These were identified as outliers during the statistical 
analyses; i.e. the two cows with a large difference between their hand and meter ELISA 
values (Y > 40). However, these two cows were kept in our analyses, because 1) refitting 
the linear model without the two outliers did not affect the conclusions, and 2) we could 
not find any logical reason (e.g. obvious laboratory mistakes) for removing them. One of 
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the false negative samples was from a first-per-meter cow (i.e. no possibility for 
carryover), while the other one was preceded by a positive cow. Moreover, the linear 
model suggested that the potential carryover effect was not significant when low-titer (or 
even medium-titer) positive cows were preceded by low-titer cows at the same meters. 
According to our results, therefore, the potential diluting effects of carryover on 
generating extra false negative results would not be concerning. Hence, we did not 
consider changing the interpretation of the lower ELISA cut-off of 10. 
This study was only focused on carryover of BLV antibodies using an ELISA test. 
However, the issue of carryover might be of concern in diagnosing other important 
infectious diseases of dairy cattle through DHI-process, particularly when methods with 
high analytical sensitivity such as ELISA and PCR are applied. Therefore, conducting 
similar studies on the other commonly tested pathogens is recommended to clarify and 
mitigate such detrimental effects. 
4.5.1 Conclusions 
Carryover of BLV antibodies at shared milk meters was significant. For low-titer 
cows (e.g. true negatives), the carryover effect was positively associated with the titer of 
the preceding cows. This could result in generating false positive results in the BLV 
antibody-ELISA test on meter-collected samples from DHI procedures. For meter-
collected samples, if we only rely on the dichotomous test results with the original cut-
off, the consequences can be economically substantial. Thus, defining a suspicious 
category for the ELISA titers, and recommending a retest on the samples falling within 
this range would be very helpful in reducing the false positive rate. 
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Table 4.1. Herd characteristics and Milk-ELISA results for antibodies against bovine 
leukemia virus (BLV) on 8 study farms from Prince Edward Island, Canada 
 
Farm 
Prevalence 
level
1 
Lactating 
herd size 
Selected 
meters 
Tested 
cows 
Positives in 
meter
2 
Positives in 
hand
2 
1 Low 49 3 27 0 0 
2 Low 83 4 28 4 4 
3 Medium 57 4 22 15 11 
4 Medium 46 2 12 5 4 
5 High 62 3 30 24 23 
6 High 126 4 48 35 25 
7 Very high 76 3 37 27 23 
8 Very high 64 3 32 24 20 
Total - 563 26 236 136 110 
1
Predicted levels of within-herd prevalence of BLV, based on a companion study 
(Chapter 5). 
2
Number of cows testing positive at the recommended ELISA cut-off of 10 (percent 
positivity). 
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Table 4.2. Results of the final linear regression model, evaluating the effect of ELISA 
titers (X) for 207 study cows on the potential carryover (Y) of antibodies against bovine 
leukemia virus. 
Variable 
a 
Coefficient SE
 
 95% CI 
X1 0.009 0.064  -0.143 0.167 
X2 0.186 0.028  0.119 0.253 
X1X2 -0.003 0.001  -0.004 -0.002 
Constant  3.501 1.906  -1.006 8.007 
a 
X1: hand ELISA value for a cow; X2: meter ELISA value for the preceding cow (before 
X1); X1X2: the interaction term between X1 and X2.  
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Table 4.3. Cross-classification of milk ELISA results for antibodies against bovine 
leukemia virus (BLV) from paired hand- and meter-collected samples in 236 study cows. 
 
 
Hand samples 
Meter samples
1 
 
Total PPmeter < 10 10 ≤ PPmeter ≤ 45 PPmeter > 45 
- Suspicious +  
- 98 26 2 126 
+ 2 4 104 110 
Total 100 30 106 236 
1
The range of ELISA results in percent positivity for meter-collected samples (PPmeter) 
has been divided into 3 categories at the two cut-off values of 10 (original) and 45 
(adjusted).  
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Figure 4.1. Scatter plot of Milk-ELISA results (percent positivity) for antibodies against 
bovine leukemia virus in paired hand- and meter-collected milk samples from 236 study 
cows. The two overlaid solid lines represent the recommended cut-off of 10, and the 
dashed line represents the adjusted cut-off of 45. 
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Figure 4.2. Interaction plot illustrating the realtionship between predicted difference of 
paired hand- and meter-collected ELISA results (Y-axis; PPmeter - PPhand) and meter-
collected results of preceding cows (X-axis; PPmeter-1), at different levels of hand-
collected results (PPhand) for antibodies against bovine leukemia virus in 207 study 
cows. Low, medium, and high levels of antibody represent 0, 30, and 60 percent 
positivity values for hand-collected samples, respectively. 
  
102 
 
 
Figure 4.3. Sensitivity/specificity plot against all possible cut-off values for paired hand- 
and meter-collected Milk-ELISA results for bovine leukemia virus antibodies in 236 
study cows. Hand samples were the dichotomized reference standard to the continuous 
meter values (percent positivity). The vertical solid line represents the recommended cut-
off of 10, and the vertical dashed line represents the adjusted cut-off of 45. 
 
  
103 
 
 
CHAPTER 5 
 
 
 
PREDICTING WITHIN-HERD PREVALENCE OF INFECTION 
WITH BOVINE LEUKEMIA VIRUS USING BULK-TANK MILK 
ANTIBODY LEVELS 
 
 
 
 
 
 
 
This chapter is in press in the Preventive Veterinary Medicine (without any change): 
 
“Nekouei, O., H. Stryhn, J. VanLeeuwen, D. Kelton, P. Hanna and G. Keefe. 2015. 
Predicting within-herd prevalence of infection with bovine leukemia virus using bulk-
tank milk antibody levels. Prev. Vet. Med. doi:10.1016/j.prevetmed.2015.10.009.”  
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5.1 Abstract 
Enzootic bovine leukosis (EBL) is an economically important infection of dairy 
cattle caused by bovine leukemia virus (BLV). Estimating the prevalence of BLV within 
dairy herds is a fundamental step towards pursuing efficient control programs. The 
objectives of this study were: 1) to determine the prevalence of BLV infection at the herd 
level using a bulk-tank milk (BTM) antibody ELISA in the Maritime region of Canada (3 
provinces); and 2) to develop appropriate statistical models for predicting within-herd 
prevalence of BLV infection using BTM antibody ELISA titers. 
During 2013, three monthly BTM samples were collected from all dairy farms in 
the Maritime region of Canada (n = 623) and tested for BLV milk antibodies using a 
commercial indirect ELISA. Based on the mean of the 3 BTM titers, 15 strata of herds (5 
per province) were defined. From each stratum, 6 herds were randomly selected for a 
total of 90 farms. Within every selected herd, an additional BTM sample was taken 
(round 4), approximately 2 months after the third round. On the same day of BTM 
sampling, all cows that contributed milk to the fourth BTM sample were individually 
tested for BLV milk antibodies (n = 6111) to estimate the true within-herd prevalence for 
the 90 herds. The association between true within-herd prevalence of BLV and means of 
various combinations of the BTM titers was assessed using linear regression models, 
adjusting for the stratified random sampling design. 
Herd-level prevalence of BLV in the region was 90.8%. In the individual testing, 
30.4% of cows were positive. True within-herd prevalences ranged from 0 to 94%. All 
linear regression models were able to predict the true within-herd prevalence of BLV 
reasonably well (R
2 
> 0.69). Predictions from the models were particularly accurate for 
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low-to-medium spectrums of the BTM titers. In general, as a greater number of the four 
repeated BTM titers were incorporated in the models, narrower confidence intervals 
around the prediction lines were achieved. The model including all 4 BTM tests as the 
predictor had the best fit, although the models using 2 and 3 BTM tests provided similar 
results to 4 repeated tests. Therefore, testing two or three BTM samples with 
approximately two-month intervals would provide relatively precise estimates for the 
potential number of infected cows in a herd. The developed models in this study could be 
applied to control and eradication programs for BLV as cost-effective tools.  
5.2 Introduction 
Enzootic bovine leukosis (EBL) is an important infection of dairy cattle 
worldwide which is caused by bovine leukemia virus (BLV). The virus is transmitted 
through infected blood lymphocytes (Gillet et al., 2013). Premature culling, death, and 
condemnation of carcasses at slaughter due to lymphoma, impaired immune function, as 
well as restrictions on international trade of infected cattle and their products are among 
the most significant economic losses attributed to the disease (Sandev et al., 2000; 
Bartlett et al., 2014). 
Many European countries, including the UK, France, Germany, Spain, the 
Scandinavian countries, Belgium, and the Netherlands, are officially free from EBL 
(Annual EU report, 2013). Some other countries, such as Japan, the United States, and 
Argentina, have actively been working on addressing their BLV problems in recent years 
in order to develop cost-effective programs for their dairy industries (Ott et al., 2003; 
Monti et al., 2007; Murakami, 2009; Rodriguez et al., 2011). 
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In different provinces of Canada, there have been a number of serological studies 
which have estimated prevalence and impact of BLV infection. In 1980, the national 
prevalence of BLV infection in Canadian dairy herds was estimated at 40.5%, while only 
9.3% of tested cattle were positive (Samagh and Kellar, 1982). However, 15 to 20 years 
later, infection levels appeared to have substantially increased. Sargeant et al. (1997) 
indicated 69.6% of the 102 tested dairy herds, and 23% of the 1330 tested cows in 
Ontario were positive to BLV. VanLeeuwen et al. (2001) reported that 70% of herds in 
the Maritime region of Canada (including provinces of Prince Edward Island (PE), New 
Brunswick (NB), and Nova Scotia (NS)) had at least one infected cow, while the 
prevalence of infection at the cow level was estimated at 20.8%. Similar studies have 
revealed a high prevalence of BLV infection across the country (VanLeeuwen et al., 
2005; VanLeeuwen et al., 2006; Scott et al., 2006). Nevertheless, there is still no broad-
based program for controlling EBL in Canada. 
Control of EBL at the national level usually consists of one or more of the 
following approaches: management interventions; test and segregation; and test and 
slaughter. Selection and success of each strategy are heavily dependent on having a 
reliable estimate of the within-herd prevalence (Bartlett et al., 2014). Attaining a 
reasonably valid estimate of the within-herd prevalence would be a fundamental step 
towards pursuing efficient control and eradication programs for BLV in every dairy herd. 
Individual serum or milk sampling from all cows on a dairy farm would provide an 
accurate measure of BLV infection prevalence; however, it would demand a great deal of 
time, labour, and cost. Therefore, in order to motivate farmers and veterinarians to 
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maximum participation in future comprehensive control programs, a cost-effective 
screening or monitoring tool for BLV at the herd level would be desirable. 
Using bulk-tank milk (BTM) samples, collected by the dairy herd improvement 
(DHI) companies, has become one of the most convenient and economically efficient 
mechanisms for screening for important infectious diseases in dairy cattle (Houe et al., 
1995; Attalla et al., 2010; Sorge et al., 2011). For instance, BTM ELISA has frequently 
been applied to surveillance of EBL, Johne’s disease, and bovine viral diarrhea 
(Niskanen, 1993; Bitsch and Ronsholt, 1995; Reber et al., 2012; Nielsen and Toft, 2014). 
Once cattle become infected with BLV, they remain infected for life and generate a 
continuous antibody response. This characteristic adds to the credibility of antibody-
based diagnostic techniques for BLV (Radostits et al., 2006; Monti et al., 2007). Among 
the available commercial tests for detection of antibodies against BLV, milk ELISA is a 
desirable method in large-scale herd surveillance, which has often been used for 
classification of herds as infected or non-infected (Erskine et al., 2012). However, there 
has been no evaluation of the predictive ability of BTM ELISA tests for within-herd 
prevalence of BLV. 
The objectives of this study were: 1) to determine the prevalence of BLV 
infection at the herd level using a BTM antibody ELISA in the Maritime region of 
Canada ; and 2) to develop applied statistical models for predicting within-herd 
prevalence of BLV infection using BTM antibody ELISA titers. 
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5.3 Materials and methods 
5.3.1 Herd selection for determining herd-level prevalence, and sample collection (a 
census) 
All dairy farms in the Maritime region of Canada (n = 644, in 2013) were the 
target and source populations for the herd-level prevalence part of the study. Permission 
was granted from the governing bodies of dairy producers of the three Maritime 
provinces to obtain BTM samples collected by these bodies for regulatory purposes in 
order to conduct our study. Therefore, all dairy farms in the Maritime region were the 
study population. 
During 2013, three bulk-tank milk samples (30 ml each), taken at one-month 
intervals, were obtained by the milk truck drivers on their routine milk pick-ups from the 
Maritime dairy farms. The drivers followed the standard procedures used for collection of 
samples for regulatory and payment purposes and, therefore, samples were well mixed. 
The milk samples were kept at 4oC until BLV laboratory testing commenced. All 
samples were tested for BLV antibodies using an indirect ELISA test (see subsection 2.3). 
The test results were reported as percent positivity (PP), and the cut-off value for a 
positive result on the test kit for pooled (bulk tank) milk samples was > 5, according to 
the manufacturer’s specifications.  
5.3.2 Herd and animal selection for predicting within-herd prevalence, and sample 
collection 
From the study herds in the census, a subset of herds (n = 90) was selected to 
evaluate the association between the BTM titers and within-herd prevalence of BLV 
infection. Two steps were taken to create pools of eligible farms with a broad spectrum of 
within-herd prevalences for the stratified random sampling strategy used in this part of 
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the study: 1) creation of five pools (strata) per province of increasing BTM-based herd-
level prevalence; and 2) identification of farms subscribing to monthly DHI testing. 
For step 1, the arithmetic mean of the three monthly ELISA titers for each farm 
was calculated. Based on the test cut-off, and the distribution of the test means (Figure1), 
all study farms were assigned into one of five strata within each of the three study 
provinces (a total of 15 strata), as follows:  
1) Potentially uninfected or very low-prevalence farms (mean < 5) 
2) Expected low-prevalence farms (5 ≤ mean < 40) 
3) Expected medium-prevalence farms (40 ≤ mean < 55) 
4) Expected high-prevalence farms (55 ≤ mean < 70) 
5) Expected very high-prevalence farms (70 ≤ mean)  
The reason for this stratification was to ensure that we would get BTM percent 
positivity titers across the range of possible ELISA test values (e.g. 0 to 100). This will 
lead to the most precise and representative estimates for the coefficients in our final 
regression models.  
For step 2, the source population was restricted to all DHI-registered dairy farms 
in the region (67% of all dairy farms), because of the necessary access to their monthly 
individual cow milk samples and information. Based on the number of DHI farms in each 
province, available budget, and other logistical considerations, 30 dairy farms from each 
province were targeted for recruitment. Using computer generated random numbers, six 
farms from each of the 15 strata were randomly selected for a total of 90 farms. An 
informed consent was obtained from each selected farm for conducting the BLV tests on 
their individual cow milk samples and further access to the farm information. All 
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procedures were approved by the University of Prince Edward Island Animal Care 
Committee. 
Within the 90 selected farms, an additional BTM sample (fourth round) was 
taken, approximately 2 months after the third round. On the same day, all lactating cows 
that contributed milk to the fourth BTM samples (n = 6111) were individually sampled 
via the corresponding milk meters used in every selected herd. From each milk meter, a 
30 ml milk sample was taken by the person who routinely took the DHI samples for 
Valacta (Sainte-Anne-de-Bellevue, QC) and one BROTAB (Sierra Court, CA, USA) was 
added to help preserve the sample for testing. Samples were kept at 4oC until all testing 
was completed. Based on the individual cow milk ELISA cut-off of 45 (Chapter 4), the 
proportion of positive milking cows to BLV antibodies (PP > 45) in each herd was 
determined.  
5.3.3 Laboratory testing 
After undergoing the standard components and quality analyses in the local 
laboratories in each province, the BTM samples were preserved with one BROTAB 
(Sierra Court, CA, USA) and transferred to the Maritime Quality Milk (MQM) laboratory 
located at the Atlantic Veterinary College, University of Prince Edward Island, in 
Charlottetown to be tested for BLV antibodies.  
All of the collected individual cow milk samples were submitted to the DHI 
laboratory in Charlottetown (PEI Analytical Laboratory, Charlottetown, PE) for routine 
DHI testing. Subsequent to the standard components and quality analyses, the samples 
were transferred to the MQM laboratory for BLV testing.  
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All BTM and individual cow milk samples were tested within a maximum of 
seven days from the sampling dates using a commercial indirect ELISA kit (SVANOVIR 
BLV gp51-Ab, Svanova, Uppsala, Sweden). The test results were reported as percent 
positivity values [PP = (ODcorrected sample/ODcorrected positive control) × 100, where OD is 
optical density].  
5.3.4 Statistical analyses 
All of the statistical analyses were carried out in Stata 13.1 (StataCorp, College 
Station, TX. USA). 
5.3.4.1 Descriptive statistics 
If a BTM test was positive (PP > 5) in any of the three rounds of sampling, the 
farm was considered infected with BLV for the herd-level prevalence calculations. 
True within-herd prevalence of BLV infection (TP) was estimated for each of the 
selected herds using the following formula (Dohoo et al., 2009): 
TP = (AP + Sp – 1)/(Se + Sp – 1) 
Where AP is apparent prevalence of BLV infection within the study herds; sensitivity 
(Se) and specificity (Sp) of the individual ELISA test at the applied threshold of 45 were 
0.955 and 0.984, respectively (Chapter 4). 
Correlations between the repeated BTM ELISA results for all herds were assessed 
by calculating the concordance correlation coefficients between every pair of the 
sampling rounds.  
5.3.4.2 Analytical statistics 
Several linear regression models were built to predict the true within-herd 
prevalence for the 90 selected herds based on their BTM ELISA titers. To satisfy the 
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assumptions of the linear regression models, the estimated true within-herd prevalence of 
BLV was square-root transformed and used as the outcome of interest (Y), and the means 
of plausible combinations of the BTM ELISA titers were examined to serve as the 
predictor of interest (X), in six separate modeling scenarios as follows: 
1) Only round 4 (concurrent BTM and individual cow milk samples; X1) 
2) Mean of rounds 4 and 3 (X2) 
3) Mean of rounds 4, 3, and 2 (X3) 
4) Mean of rounds 4, 3, and 1 (X4) 
5) Mean of all 4 rounds (X5) 
6) Mean of rounds 3, 2, and 1 (X6) 
Number of lactating cows within each herd (lactating herd size) was included in 
all models to control for the potential dilution effects due to pooled milk in the bulk 
tanks. The stratified random sampling design was also taken into account in all of the 
scenarios, by incorporating sampling weights and finite population corrections 
corresponding to each of the 15 strata. A diagram for predicted within-herd prevalence 
versus BTM ELISA titers was generated to illustrate and compare the resultant functions 
from the six final models. 
The within-herd prevalence of BLV for all study farms was predicted and graphed 
in order to exhibit a general picture of the infection levels in the regional dairy herds. For 
this purpose, the means of the first three monthly BTM ELISA titers for each herd were 
used as the predictor (corresponding to scenario X6). 
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5.4 Results 
Overall, 623 dairy farms (97% of all regional dairy farms in 2013) completed 
the first part of the study. Of the 623 herds, 566 (90.8%) were found to be positive to 
BLV antibodies on at least one of the three monthly BTM ELISA tests. Based on 
these results, herd-level prevalence of BLV in the Maritimes is presented in Table 1. 
As depicted, the three study provinces had quite similar herd-level prevalences and 
there was no apparent difference in the infection level between DHI-registered herds 
and all herds collectively. 
Concordance correlations between the three monthly BTM ELISA titers for 
all herds, as well as between the four rounds for the 90 selected herds are presented in 
Table 2. The calculated coefficients indicated reasonably high correlations (minimum 
of 72.3%) between the results from all pairs of the sampling rounds. 
The mean lactating herd size for the 90 selected herds for individual testing 
was 68 (range: 23 – 287), and 78 herds (87%) had fewer than 100 lactating cows. In 
the individual testing, 30.4% (1860/6111) of the cows were positive. Among the 
tested cows, 90% were Holstein. True within-herd prevalence of BLV infection 
ranged from 0 to 94%. 
Lactating herd size was found to be clearly non-significant in all of the examined 
scenarios (P > 0.2) and it did not change the other estimates in the linear regression 
models (of the square root of true within-herd prevalence of BLV). As a result, it was not 
included in the final models. Final models for the six scenarios of interest are provided in 
Table 3. A strong positive association (P < 0.001) between the square root transformed 
true within-herd prevalence and BTM ELISA titer was identified in all scenarios. When 
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only concurrent BTM results were used as the predictor (X1), two significant outliers 
were detected. Incorporating BTM results from the preceding rounds improved the fit and 
predictive ability of the models (increasing the corresponding coefficient of 
determination, R2).  
Figure 2 illustrates the final prediction functions, by the various scenarios. 
According to the graph, there is no clear distinction in the predicted within-herd 
prevalence among the functions for low-to-medium values of BTM ELISA (i.e. PP < 55). 
For instance, a herd with PP = 40 would roughly be expected to harbor 17.8 % (16.0-
19.7%) and 18.1% (12.9-25.3%) antibody-positive lactating cows, using the two extreme 
scenarios, X5 and X1 respectively. Incorporating more rounds of BTMs led to a narrower 
uncertainty (greater precision) about the prediction lines, especially at low percent 
positivity (Appendix B). As the BTM titer increased, above 55, the corresponding 
predicted within-herd prevalences became more divergent among the models; but this 
variation still did not appear to be substantial. 
A scatter plot displaying the association between the predicted within-herd 
prevalence and the mean value of all repeated BTM ELISA titers (scenario X5) for the 
selected 90 herds is presented in Figure 3, along with the line of best fit and its 95% 
confidence interval. The curve seems to fit the data well, and the confidence interval 
around the prediction line is fairly narrow, expanding somewhat as the prevalence 
increases. 
Using the X6 model, predicted within-herd prevalences for all herds in the region 
(n = 623) were determined from the means of the first three monthly BTM ELISA titers 
to exhibit a general picture of the infection levels in the region. Results suggested that 
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41.4% of the herds (n = 258) had potentially > 50% BLV-positive lactating cows, with 39 
herds (6.9% of the total positive herds) being > 90% BLV-positive. Mean of the predicted 
within-herd prevalences for infected herds (n = 566) was estimated at 0.487 (SD = 
0.255). Figure4 illustrates the frequency distribution of these predicted within-herd 
prevalences of BLV infection for the infected herds. 
5.5 Discussion 
Our results indicated that the prevalence of infection with BLV at the herd level in 
the Maritime region of Canada was very high. This is most likely due to dairy farmers in 
Canada not effectively controlling BLV transmission (Chapter 2). Herd-level prevalence 
of BLV infection in the Maritime region rose from 70% (60.3% - 79.7%) in 1998 
(VanLeeuwen, et al., 2001) to over 90% in 2013 (present study). In the United States, as 
a part of the 2007 national dairy study (APHIS-USDA report, 2008), 83.9% of tested 
herds were found to be positive using BTM ELISA. Volunteer programs for certifying 
BLV-free status have been implemented by a small percentage of the dairy herds in North 
America (e.g. genetically valuable herds), in order to authorize the exportation of their 
genetic products to other countries, which demand a BLV-negative status (Reed, 1981; 
Bartlett et al, 2014). All of the available evidence indicates the necessity for decisive 
action against EBL. However, this is not appealing to the industry unless it employs 
inexpensive, efficient tools such as the suggested modeling approach in this study. 
Measuring antibodies and other diagnostic targets in BTM as an indicator of herd 
status has historically been used for monitoring and control of important infectious 
diseases in dairy cattle, including EBL, BVD, and Johne’s disease (Eloit et al., 1990; 
Beaudeau et al., 2001; Attalla et al., 2010; Sorge et al., 2011). Our results demonstrate 
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that BTM ELISA is not only a highly cost-effective tool to dairy herds for monitoring 
and screening for BLV infection, but also for predicting the within herd prevalence. 
Application of BTM antibody ELISA results for predicting the potential number of 
infected cows within herds would lay a strong foundation for pursuing economical BLV 
control programs. 
In order to develop a reliable, applied statistical model for prediction of the 
within-herd prevalence, we were required to achieve reasonably strong correlations: 1) 
between the repeated rounds of BTM ELISA measurements, confirming the consistency 
of the test results between samples; and 2) between the outcome variable (true within-
herd prevalence) and the BTM ELISA titer (i.e. attaining an acceptable R
2
 in the final 
models). In our study, correlations between the repeated rounds of BTM titers were over 
0.72 in all pairings. The correlation was above 80% for contiguous monthly BTM 
samples, but slightly decreased with longer than monthly time intervals between the 
samples. In general, the prevalence of BLV in herds from endemic areas remains 
relatively steady over time (Radostits et al., 2006). This characteristic of BLV infection 
would add to the credibility of prediction methods. Fluctuations in the repeated BTM 
titers could be mainly attributable to changing composition of lactating herds at sampling 
(i.e. every month, a number of milking cows are dried off, and some fresh heifers or dry 
cows join the milking herd after parturition). Addition or elimination of certain cows can 
influence the BTM titer. Cows in advanced stages of the infection (e.g. persistent 
lymphocytosis) often produce high levels of virus and circulating antibodies (Juliarena et 
al., 2007). Another source of variation between repeated BTM titers could be differences 
in laboratory measurements over time (Nielsen, 2002). As for the second requirement, the 
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R
2
 of the models containing at least 2 BTM samples all were above 75% (Table 3), 
demonstrating good predictive ability to the proposed BTM methodology for predicting 
true within-herd prevalence. 
Although using the concurrent BTM sample as the only predictor (X1) led to 
acceptable estimates for BLV within-herd prevalence, the uncertainty around the 
prediction line was considerably wider than for the other scenarios using at least two 
BTM samples, particularly at low prevalences (Appendix B). Because this scenario also 
had poorer fit compared to the other scenarios, we do not recommend application of the 
one-sample strategy in practice. In contrast, incorporating more of the BTM samples 
collected over appropriate time intervals, and using the corresponding means as the 
model predictor, yielded more reliable results. As additional BTM rounds were engaged 
in the models, fit and predictive ability of the models improved, and outliers were not as 
extreme as they were in scenario X1 (Appendix B). However, using all 4 rounds of BTM 
results (X5) did not add substantial gain compared to the other scenarios (X2-X4 and X6), 
and demanded more cost and effort. Recommendations should be made in light of trade-
offs between a farmer’s desire for additional precision (dependent on the management 
goals) versus the delays and costs imposed from additional rounds of BTM sampling. For 
instance, if only a basic sense of within-herd prevalence of infection with BLV was 
needed, model X2 (2 samples, 2 months apart) could be adequate. In contrast, a slightly 
more accurate estimate of the within-herd prevalence can be generated using 3-sample 
models such as X4. In high-prevalence herds (PP > 55), in order to monitor and document 
a decreasing trend of the prevalence due to an undertaken control program, models which 
provide greater accuracy would be recommended. Farmers with strong interest in 
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controlling BLV could adopt ongoing BTM screening. The two-month intervals would 
likely take most dry cows from the preceding rounds of sampling into account. 
Despite the fact that our source population in this study was DHI-registered dairy 
farms (410/623), the source population was representative of our target population with 
respect to structure, management, and production parameters. In addition, there was no 
substantive difference in the herd-level prevalence of BLV between DHI herds and all 
herds (as presented in Table 1). Therefore, the corresponding model using the first three 
tests (X6) was applied to predict the within-herd prevalence for all regional dairy farms. 
As our results suggested, within-herd prevalence of BLV in infected herds in the region 
was also high, which further emphasized the importance of taking immediate control 
measures. 
The persistent nature of BLV infection, continuous antibody response, and 
absence of a vaccination make this pathogen a good candidate for integrating exact, 
quantitative prediction models into control programs, unlike other important infections of 
dairy cattle (e.g. BVD and Johne’s disease) (Radostits et al., 2006; Gutierrez et al., 2014). 
Nielsen and Toft (2014) demonstrated a significant association between repeated BTM 
ELISA results and within-herd prevalence of infection with Mycobacterium avium subsp. 
paratuberculosis (MAP) in Danish dairy herds. However, the practical application of 
BTM testing for MAP was found to be limited because the BTM responses were in a 
relatively narrow range of the ELISA test, as well as due to substantial uncertainty 
around the prediction line. In the present research, we initially designed our study 
(implementing a stratified random sampling strategy) to obtain BTM titers over an 
expected full spectrum of ELISA values. Consequently, relatively narrow confidence 
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intervals about the prediction lines were achieved. Eiras et al. (2012) reported strong 
correlations between the within-herd seroprevalence and BTM antibody levels against 
BVD virus, using different ELISA methods in Galicia, Spain; however, they did not 
present any quantitative models. Beaudeau et al. (2001), in a similar research project on 
BVD, suggested a linear regression model with high correlation between BTM results 
and within-herd prevalence of BVD in French dairy herds. However, for BVD, its 
unstable nature, the variety of clinical manifestations, the abundance of transiently 
infected cows in infected herds, along with the complications due to active vaccination 
programs (Brodersen, 2014) would restrict the predictive ability and broad application of 
the potential models based solely on BTM ELISA values. 
Although in several studies, BTM ELISA has been used for classification of herds 
as non-infected or infected with BLV (Eloit et al., 1990; Sargeant et al., 1997; Sorge et 
al., 2011; Reber et al., 2012), this was the first time that a quantitative approach for 
predicting within-herd prevalence of BLV was investigated. Determining the 
approximate number of infected cows in a herd can be of particular importance when a 
decision on adopting the most suitable control or eradication strategy is to be made. For 
instance, if only a few positive cows in a herd were expected, eradication measures such 
as test and removal could economically be justified. If a low prevalence of the infection 
(e.g. < 20%) was predicted, then a test and segregation strategy could be desirable 
(Bartlett et al., 2014). Our models indicated high precision (narrow uncertainty) in the 
predictions for low-to-medium BTM ELISA titers, giving confidence to farmers who 
decide to make eradication or segregation decisions. The fluctuations and relatively wider 
uncertainty for high titers (e.g. PP > 55) should not be concerning to farmers with results 
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in this range because decision rules (i.e. farm protocols) for farms with estimated 
prevalence above 30% would be similar; usually including standard management 
programs in order to reduce the within-herd transmission of BLV (Casal et al., 1990; 
Bartlett et al., 2014). For these herds with medium-to-high levels of within-herd 
prevalence, which is the situation for many dairy herds in North America, management 
strategies without removal or segregation for controlling BLV are preferred due to the 
considerable cost (and/or impracticality) of removal and segregation schemes (Sandev et 
al., 2000; Bartlett et al., 2014).             
The potential dilution effect from a large number of cows that contribute milk to a 
bulk tank could theoretically lead to under-estimation of the within-herd prevalence. In 
our study, however, lactating herd size (representing the potential dilution effect) did not 
show any significant effect on the within-herd prevalence of BLV. This finding was in 
agreement with the results from another study by Beaudeau et al. (2001) on BVD. One of 
the likely reasons for this finding could be relatively small lactating herd size for most of 
the herds in our study; 78/90 (87%) herds had a lactating herd size of less than 100, and 
the rest were between 100 to 287. For most Canadian dairy herds, this issue would not be 
concerning because our study farms were representative of the most dairy farms in 
Canada with respect to the lactating herd size. The mean lactating herd size in Canada is 
70 – 80 cows (Canada dairy-info, 2015), which is very close to the mean of 68 cows in 
our study herds. However, lactating herd size should be taken into consideration when 
similar modeling approaches are to be practiced in large dairy herds elsewhere. 
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5.5.1 Conclusions 
Prevalence of infection with BLV at the herd and cow levels on dairy farms of the 
Maritime region of Canada was very high, indicating the necessity for a broad-based, 
comprehensive response. Obtaining an estimate of the number of infected cows on a farm 
would be a fundamental step towards adopting appropriate control or eradication 
strategies for that farm. The statistical models developed in this study were able to predict 
true within-herd prevalence of BLV reasonably well, using 2-4 BTM ELISA titers over 
2-4 months. However, the choice of one model would primarily depend on different 
purposes of BTM testing in dairy farms with various levels of BLV infection prevalence 
(e.g. for reducing high-prevalence of BLV, or eliminating the infection from low-
prevalence herds). The presented methodology offers many advantages, including being 
convenient (BTM samples can easily be accessed), efficient (as few as 2 BTM samples 
could be used), and inexpensive (individual cow samples not needed). Therefore, the 
methodology could readily be integrated into future BLV control and surveillance 
programs. Application of the presented approach could cautiously be extended to dairy 
farms from other regions with similar structure and management strategies.  
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Table 5.1. Herd-level prevalence of infection with bovine leukemia virus for all 623 dairy 
herds from the Maritime region of Canada, by province (2013). 
Province
 
No. of  
(tested) herds  
No. of  
positive herds
 a
 
Herd level  
prevalence (%)
b 
All  DHI 
c 
All DHI All DHI 
New Brunswick 202 142 179 120 88.6 84.5 
Nova Scotia 237 154 219 141 92.4 91.6 
Prince Edward Island 184 114 168 102 91.3 89.5 
Total  623 410 566 363 90.8 88.5 
a 
A herd was positive if any of the 3 monthly BTM ELISA values was equal or larger 
than 5. 
b
 Number of positive herds/number of herds (a census). 
c 
Only herds registered on dairy herd improvement (DHI) programs (410/623).  
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Table 5.2. Concordance correlations among all rounds of bulk-tank milk ELISA results 
for infection with bovine leukemia virus in Canadian Maritime dairy herds.   
CCC (SE)
a
 All 623 herds 90 selected herds 
b 
Rounds 1 & 2 0.822 (0.012) 0.856 (0.028) 
Rounds 1 & 3 0.723 (0.019) 0.766 (0.044) 
Rounds 1 & 4 - 0.732 (0.048) 
Rounds 2 & 3 0.805 (0.014) 0.822 (0.034) 
Rounds 2 & 4 - 0.751 (0.042) 
Rounds 3 & 4 - 0.800 (0.037) 
a 
Concordance correlation coefficient and the corresponding standard error. 
b 
In the 90 selected herds, there was an additional round of sampling (round 4).  
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Table 5.3. Final linear regression models for predicting within-herd prevalence of 
infection with bovine leukemia virus (Y), using different combinations of bulk-tank milk 
ELISA results (X) in 90 study dairy herds. 
Scenario of interest Final model
 a 
SE for slope 
b 
R
2 
(%)
c 
Only 4 (X1) Y = (0.00773 X1 + 0.11121)
2 
0.00065 69 
Mean of 4 & 3 (X2) Y = (0.00895 X2 + 0.05706)
2
 0.00040 75 
Mean of 4 & 3 & 2 (X3) Y = (0.00945 X3 + 0.04718)
2
 0.00050 78 
Mean of 4 & 3 & 1 (X4) Y = (0.00944 X4 + 0.02877)
2 
0.00046 82 
Mean of all 4 (X5) Y = (0.00956 X5 + 0.03636)
2 
0.00044 82 
Mean of 3 & 2 & 1 (X6) Y = (0.00899 X6 + 0.08282)
2 
0.00046 76 
a Y: predicted true within-herd prevalence; and X: BTM ELISA titer (mean of titers from 
different rounds).   
b 
Standard error for the corresponding coefficient of X (slope) in the final models, on 
square root transformed scale. The coefficients were all highly significant (P < 0.001). 
c
 Coefficient of determination in percentage.  
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Figure 5.1. Frequency distribution of the mean of three monthly bulk-tank milk ELISA 
results (percent positivity) for infection with bovine leukemia virus in 623 dairy farms 
from the Maritime region of Canada (2013). Four dashed lines indicate the cut-points for 
categorizing the herds into the five prevalence-level groups.     
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Figure 5.2. Predictive functions for five final models predicting within-herd prevalence of 
infection with bovine leukemia virus (Y axis), versus six different scenarios of repeated 
bulk-tank milk ELISA titers (percent positivity; X axis), in 90 selected farms from the 
Maritime region of Canada. X1: using round 4 scenario; X2: mean of rounds 3 and 4; X3: 
mean of rounds 2, 3, and 4; X4: mean of rounds 1, 3, and 4; X5: mean of rounds 1, 2, 3, 
and 4; X6 mean of rounds 3, 2, and 1. Note that X3 and X5 scenarios are not 
distinguishable (mostly overlapping). 
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Figure 5.3. Scatter diagram for prediction of the within-herd prevalence of infection with 
bovine leukemia virus (Y axis), versus the mean value of the four available repeated 
bulk-tank milk ELISA titers (percent positivity; X axis); from the equation: Y = (0.00956 
X5 + 0.03636)2 (scenario X5). Dashed lines around the solid prediction-line represent the 
95% confidence interval for the prediction (after back-transformation to original scale). 
Each point represents one of the 90 selected farms from the Maritime region of Canada.  
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Figure 5.4. Frequency distribution of the predicted within-herd prevalence of infection 
with bovine leukemia virus (based on the corresponding model, X6) for 566 infected 
dairy farms from the Maritime region of Canada.  
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CHAPTER 6 
 
 
 
DIAGNOSTIC PERFORMANCE OF AN INDIRECT ELISA TO 
DETECT BOVINE LEUKEMIA VIRUS ANTIBODIES IN BULK-
TANK MILK SAMPLES 
 
 
 
 
 
 
 
 
This chapter has been accepted for publication in the Canadian Veterinary Journal as a 
brief communication (without substantive change): 
“Nekouei, O., J. Durocher and G. Keefe. 2015. Diagnostic performance of an indirect 
ELISA to detect bovine leukemia virus antibodies in bulk-tank milk samples. Can. Vet. 
J.”  
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6.1 Abstract 
The objective of this study was to assess the diagnostic performance of a 
commercially available ELISA for detecting bovine leukemia virus (BLV) antibodies in 
bulk-tank milk (BTM) samples from Eastern Canada. The study population consisted of 
133 dairy farms, including 8358 lactating cows, from provinces of Prince Edward Island 
(PE), New Brunswick (NB), Nova Scotia (NS), and Quebec (QC). Within every herd, one 
BTM sample and samples from all cows that contributed milk to the BTM on that day 
were collected and tested for BLV-antibodies by an ELISA. One hundred and eight tested 
herds (81.2%) were found to be truly infected, based on the individual cow test results. 
Using estimated true within-herd prevalences of BLV as the reference standard, 
sensitivity and specificity of the BTM test at the determined optimum cut-point of 5 
(percent positivity) were estimated at 97.2% (92.1 – 99.4%) and 100% (86.3 – 100%), 
respectively. The test was therefore recommended as a valid, cost-effective tool for large-
scale BLV screening and monitoring schemes. 
6.2 Introduction 
Enzootic bovine leukosis (EBL) is an economically important disease of dairy 
cattle caused by bovine leukemia virus (BLV). The virus is transmitted through infected 
blood lymphocytes. Premature culling, death, and condemnation of carcasses at slaughter 
due to lymphoma, abnormal immune function, as well as restrictions on international 
trade of infected cattle and their products are among the most significant economic losses 
attributed to the disease (Sandev et al., 2000; Bartlett et al., 2014). 
Many European countries are now officially free from EBL, whereas prevalence 
of the infection in North America has been high and appears to have a rising trend 
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(Bartlett et al., 2014; Chapter 5). For instance, in the Maritime region of Canada, herd-
level prevalence of the infection from 70% in 1998 (VanLeeuwen et al., 2001) reached to 
over 90% in 2013 (Chapter 5). 
Using bulk-tank milk (BTM) samples has become one of the most convenient and 
economically efficient procedures for screening for important diseases in dairy herds, 
including EBL (Sargeant et al., 1997b; Sorge et al., 2011b). Among available commercial 
tests for detection of BLV-antibodies, milk ELISA has been documented as a desirable 
method with great performance in large-scale surveillance programs (Gutierrez et al., 
2001; Erskine et al., 2012c). However, applying commercial ELISA tests, particularly to 
the pooled samples (e.g. BTM), could lead to variable levels of uncertainty in the results. 
Several factors, including study region, herd (pool) size, sampling procedures, and 
transfer process can potentially contribute to the variable test results. Therefore, it has 
been recommended that the validity of diagnostic tests should be evaluated in different 
populations before integrating the tests in large-scale control and eradication programs 
(Christensen and Gardner, 2000; Greiner and Gardner, 2000). The objective of this study 
was to assess the diagnostic performance (sensitivity and specificity) of a commercially 
available ELISA for detecting BLV-antibodies in BTM samples from Eastern Canada; in 
order to validate the routine application of this test to the BLV monitoring programs 
implemented in the region. 
6.3 Materials and methods 
6.3.1 Study population and sample collection 
The study population consisted of 133 dairy herd improvement (DHI)-registered 
dairy herds, including 8358 lactating cows, from four eastern provinces of Canada 
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(Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), and Quebec 
(QC)). During 2013, 30 farms were randomly selected from each of PE, NB, and NS (a 
total of 90 farms) based on a wide range of BLV within-herd prevalences (Chapter 5). In 
2014, a similar study was carried out on 43 purposively selected dairy farms from 
Quebec. The Quebec herds were also selected from a potential wide spectrum of 
prevalences, according to the available data from historic surveys. One BTM sample was 
obtained from every selected farm, and on the same day of the BTM sampling, all 
lactating cows that contributed milk to the BTM were also individually sampled via the 
corresponding milk meters. 
6.3.2 Laboratory testing 
Individual cow and BTM samples (30 ml each) from PE, NB, and NS were 
transferred to the Maritime Quality Milk (MQM) laboratory located in the University of 
Prince Edward Island, in Charlottetown to be tested for BLV-antibodies. All Quebec 
samples were submitted to the Valacta central laboratory (Sainte-Anne-de-Bellevue, QC) 
for BLV testing. All samples were preserved with BROTAB (Sierra Court, CA, USA) 
and tested in a maximum of seven days from the original sampling dates using a 
commercial indirect ELISA (Svanovir BLV gp51-Ab, Svanova, Uppsala, Sweden). The 
test results were reported as percent positivity (PP) values [PP = (ODcorrected 
sample/ODcorrected positive control) × 100, where OD = optical density]. 
6.3.3 Statistical analyses 
All of the statistical analyses were conducted in Stata 13.1 (StataCorp, College 
Station, TX. USA).  
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To determine the apparent within-herd prevalence of BLV-antibodies (AP), 
number of positive cows (PP > 45) was divided by the number of lactating (tested) cows 
for every herd. True within-herd prevalence of BLV infection (TP) was then estimated 
for each of the selected herds using the following formula (Dohoo et al., 2009): 
TP = (AP + Sp –1)/(Se + Sp –1) 
Where AP is the apparent prevalence of BLV infection within the study herds; 
sensitivity (Se) and specificity (Sp) of the individual ELISA test at the applied threshold 
of 45 were 95.5% and 98.4%, respectively (Chapter 4). The true within-herd prevalence 
was regarded as the reference standard for evaluating the diagnostic performance of the 
pooled-level application of the BTM ELISA. If the true within herd prevalence was zero 
(i.e. all cows were negative), the herd was considered as uninfected; and if it was above 
zero (i.e. at least one positive cow was present), the herd was considered as infected with 
BLV. A two-graph receiver operating characteristic (ROC) analysis was carried out to 
determine the optimal cut-point on BTM ELISA values using the defined dichotomized 
reference standard. 
6.4 Results 
Based on the true within-herd prevalence of BLV, 81.2% (108/133) of the study 
herds were found to be infected (i.e., true positive herds). Of 8358 tested cows (90% 
Holstein), 2661 (31.8%) were positive to BLV milk-antibodies in the individual cow 
testing. Descriptive statistics for the study herds, by province, are presented in Table 6.1. 
The mean of BLV true within-herd prevalence for the 108 infected herds was 0.39 (SD = 
0.27). Figure 6.1 displays the distribution of BLV true within-herd prevalence for the 
study herds. 
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From the two-graph ROC analysis (Figure 6.2), maximum accuracy for BTM 
ELISA titers was achieved at 2.1 and 7.2 (percent positivity), respectively. Hence, the 
midpoint of 5 (-also recommended by the manufacturer of the test kit) was considered as 
our practical cut-point value. At this cut-point, sensitivity and specificity of the BTM 
ELISA were estimated at 97.2% (95% CI: 92.1 – 99.4%) and 100% (95% CI: 86.3 – 
100%), respectively (Table 6.2). 
6.5 Discussion 
According to our established reference standard, three truly infected herds were 
tested negative by the BTM ELISA (defined as false negative herds). Each of those 3 
herds harbored only one infected cow: one herd from NS (including 53 lactating cows), 
and two herds from QC (including 37 and 47 lactating cows). In stringent eradication 
programs, repeated sampling from bulk-tank over appropriate time intervals has been 
recommended in order to compensate for the imperfect sensitivity of the BTM tests, and 
to capture as many positive animals in a herd as possible (Dohoo et al., 2009). 
Addition or elimination of some cows can be influential on the BTM titers, such 
as those at advanced stages of BLV infection (e.g. cows with persistent lymphocytosis), 
because they often produce high levels of virus and circulating antibodies (Juliarena et 
al., 2007). However, it is generally believed that the prevalence of BLV in herds from 
endemic areas (e.g. North America) remain fairly steady over time (Radostits et al., 2006; 
Chapter 5); this characteristic supports the validity of the current testing strategies (BTM 
ELISA) used in detecting BLV infection. 
We were not able to apply more sophisticated statistical analyses to our data in 
order to include some potentially important herd-level factors such as lactating herd size 
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(surrogating the potential dilution effect of BTM) because there were only 3 false 
diagnoses by the BTM test. However, this issue should not lead to any substantial bias 
since the selected herds were reasonably representative of the herds in Eastern Canada 
with regards to the main characteristics, including herd size. For instance, the average 
lactating herd size in our study was 62.8, which was very close to the average of lactating 
herd size in all four study provinces (approximately 60). 
6.5.1 Conclusions 
Applying a cut-point of 5 to the ELISA test, when it was used on BTM samples 
generated reasonably valid results. Producers whose farms are free from BLV and would 
desire to maintain their negative status or those who wish to monitor their decreasing 
trend of BLV prevalence on their farms (due to taking control measures) could efficiently 
adopt ongoing monitoring using the BTM ELISA test over appropriate time-intervals. 
Application of the BTM ELISA in other regions (particularly with large herds) should be 
validated before applying to future surveillance programs.  
139 
 
6.6 References  
Bartlett, P. C., L. M. Sordillo, T. M. Byrem, B. Norby, D. L. Grooms, C. L. Swenson, J. 
Zalucha and R. J. Erskine. 2014. Options for the control of bovine leukemia virus in 
dairy cattle. J. Am. Vet. Med. Assoc. 244:914-922.  
Christensen, J. and I. A. Gardner. 2000. Herd-level interpretation of test results for 
epidemiologic studies of animal diseases. Prev. Vet. Med. 45:83-106.  
Dohoo I.R., S.W. Martin, and H. Stryhn. 2009. Veterinary Epidemiologic Research, 2
nd
 
ed. Charlottetown, PE, Canada: VER Inc., pp:91-133. 
Eloit, M., F. Lamy, M. Glevarec, F. Galaup, R. Turmel, A. Vigouroux, J. J. Benet and B. 
Toma. 1990. Detection of bovine leukemia virus antibodies in bulk tank milk using 
an ELISA test: Improvement of the predictive value of results by repeated testing. 
Biologicals. 18:19-23. 
Erskine, R. J., P. C. Bartlett, T. M. Byrem, C. L. Render, C. Febvay and J. T. Houseman. 
2012. Using a herd profile to determine age-specific prevalence of bovine leukemia 
virus in Michigan dairy herds. Vet Med Int. 2012:350374-350374.  
Greiner, M. and I. A. Gardner. 2000. Epidemiologic issues in the validation of veterinary 
diagnostic tests. Prev. Vet. Med. 45:3-22.  
Gutierrez, S. E., J. F. Ferrer, E. N. Esteban, C. Rodriguez Dubra, G. L. Dolcini and G. H. 
Arroyo. 2001. Development and evaluation of a highly sensitive and specific 
blocking enzyme-linked immunosorbent assay and polymerase chain reaction assay 
for diagnosis of bovine leukemia virus infection in cattle. Am. J. Vet. Res. 62:1571-
1577.  
Juliarena, M. A., S. E. Gutierrez and C. Ceriani. 2007. Determination of proviral load in 
bovine leukemia virus-infected cattle with and without lymphocytosis. Am. J. Vet. 
Res. 68:1220-1225.  
Radostits O.M., Gay C.C., Hinchcliff K.W., Constable P.D. 2006. Veterinary Medicine: 
A textbook of the diseases of cattle, horses, sheep, pigs and goats, 10
th
 ed. Elsevier 
Saunders, New York, USA. pp:1209-1221 
Sandev N, Kostadinova N, Zarkov I. 2000. Economic problems concerning enzootic 
bovine leukosis. Agric. Econ. Manag. 45:38-41.  
Sargeant JM, Kelton DF, Martin SW, Mann ED. 1997. Evaluation of a bulk-milk ELISA 
test for the classification of herd-level bovine leukemia virus status. Prev. Vet. Med. 
31:211-221.  
140 
 
Sorge, U. S., K. Lissemore, R. Cantin and D. F. Kelton. 2011. Milk ELISA status for 
bovine leukosis virus infection is not associated with milk production in dairy cows. 
J. Dairy Sci. 94:5062-5064.  
VanLeeuwen, J. A., G. P. Keefe, R. Tremblay, C. Power and J. J. Wichtel. 2001. 
Seroprevalence of infection with mycobacterium avium subspecies paratuberculosis, 
bovine leukemia virus, and bovine viral diarrhea virus in maritime Canada dairy 
cattle. Can. Vet. J. 42:193-198.  
   
141 
 
Table 6.1. Descriptive summary for 133 study dairy herds that had all their lactating cows 
tested for bovine leukemia virus milk-antibodies, from eastern provinces of Canada. 
Province 
a 
Tested 
herds 
Lactating herd size Tested cows Positive  
cows 
a
 
Proportion  
(%) 
b
 Min Median Max 
New Brunswick 30 23 51 287 2232 845 37.8 
Nova Scotia 30 30 65.5 214 2281 460 20.2 
Prince Edward Island 30 28 52 126 1598 555 34.7 
Quebec 43 14 56 145 2247 801 35.6 
Total 133 14 52 287 8358 2661 31.8 
a 
Positive in individual milk ELISA test (percent positivity > 45). 
b
 Number of positive cows/Number of tested cows. 
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Table 6.2. Cross-classification of bulk-tank milk ELISA results at the cut-point of 5 PP 
(percent positivity) for antibodies against bovine leukemia virus (BLV) and true within-
herd prevalence of BLV in 133 study herds
a
. 
 
 
BTM ELISA
 
True within-herd  
prevalence (reference)
 
 
Total 
> 0 = 0 
PP ≥ 5 105 0 105 
PP < 5 3 25 28 
Total 108 25 133 
a
 Sensitivity and specificity of the BTM ELISA were estimated at 97.2% (92.1 – 99.4%) 
and 100% (86.3 – 100%), respectively.   
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Figure 6.1. Frequency distribution of the within-herd prevalence of infection with bovine 
leukemia virus for 133 study herds from eastern provinces of Canada. The black bar 
represents uninfected herds (25/133). 
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Figure 6.2. Two-graph receiver operating characteristic curve (ROC) illustrating 
sensitivity and specificity versus all possible cut-off values for bulk-tank milk ELISA 
results (percent positivity) for bovine leukemia virus antibodies in 133 study herds. True 
within-herd prevalence was used as the dichotomized reference standard (0; or 1 if it 
was> 0). The vertical solid line represents the recommended cut-off of 5. 
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CHAPTER 7 
 
OVERALL CONCLUSIONS 
 
 
Enzootic bovine leukosis (EBL) is an important infection of dairy cattle which is 
caused by bovine leukemia virus (BLV) (Radostits et al., 2006; Smith, 2009). Infection 
with BLV imposes substantial financial loss to the dairy industry, particularly in 
countries with high prevalence of the infection (e.g. Canada). Major monetized losses 
from the infection include premature culling, death, and condemnation of carcasses at 
slaughter due to lymphoma, production loss, lower reproductive efficiency, impaired 
immune function and susceptibility to other infections, as well as trade restrictions 
imposed on infected cattle and their products (Sandev et al., 2000; Bartlett et al., 2014). 
Prevalence of the infection in Canadian dairy herds and cows is high (over 80% 
and 30%, respectively) and continues to increase (Sargeant et al., 1997; VanLeeuwen et 
al., 2001; VanLeeuwen et al., 2005; VanLeeuwen et al., 2006; Scott et al., 2006; Chapter 
5). Nevertheless, there are no broad-based, national programs in place for controlling 
EBL in Canada. 
Overall, the objectives of the research described in this thesis were to: 1) identify 
important herd-level risk factors for BLV infection in Canada (Chapter 2); 2) assess 
lifetime effects of the infection on milk production and longevity of Canadian dairy cows 
(Chapter 3); 3) evaluate the potential carryover of BLV antibodies in shared milk meters 
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(Chapter 4); 4) to address the carryover issue by adjusting assay cut-off values in 
screening programs (Chapter 4); 5) to determine the current herd-level prevalence of the 
infection in the Maritime region (Chapter 5); 6) to develop applied statistical models for 
predicting within-herd prevalence of BLV using bulk-tank milk (BTM) antibody levels 
(Chapter 5); 7) to validate diagnostic performance of a BTM ELISA in dairy herds from 
eastern Canada (Chapter 6). 
All of the findings from the described work could eventually contribute to 
designing and conducting efficient control/management programs for BLV infection in 
Canada.  
7.1 Herd-level risk factors for BLV infection 
The focus for Chapter 2 was to identify potentially important risk factors for BLV 
infection in Canadian dairy herds, as a prerequisite to developing an effective control 
program. Of 272 herds which successfully completed the study, 78% were identified as 
BLV-positive. Among more than 15 evaluated determinants for the infection, a few of 
those were significantly associated with BLV seroprevalence at the herd-level. Herds 
with clinical cases of leukosis during the 12 months prior to sampling, as well as herds 
which purchased animals with unknown BLV infection status in the last five years, had a 
significantly greater proportion of BLV-positive animals. In the western provinces of 
Canada, changing gloves between cows during pregnancy examination was not 
statistically associated with lower seroprevalence of BLV compared with not changing 
gloves. In another part of the analyses, herds from eastern Canadian provinces and those 
not purchasing cows in the last five years were more likely to be free from BLV. 
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In general, moving towards closed herds in the cattle industry will be an efficient 
way to control different contagious diseases (including EBL), wherever possible. 
National, regional, and herd-specific BLV control programs should not only be focused 
on inhibiting virus transmission between herds by purchasing BLV-negative replacement 
animals, but also focused on decreasing BLV spread between cows (i.e. within a herd), 
particularly in herds with high prevalence of BLV infection. Applying proper count data 
models is recommended to extract all of the available information in different data sets on 
risk factors for infectious diseases of dairy cattle. 
7.2 Lifetime effects of BLV infection on longevity and milk production 
The objective in Chapter 3 was to determine the effects of BLV infection on 
lifetime milk production and longevity of dairy cows in Canada. All participant cows had 
been culled or died by the onset of the conducted historical cohort study. Overall, 4052 
cows from 348 herds were enrolled in the study. In the longevity part of this Chapter, the 
interaction term between time (the number of life lactations) and BLV-status was 
significant. Positive cows to BLV had constantly greater probability of being culled (or 
dying) than the negative cows. In the milk production portion of the study, the interaction 
term between BLV-status and lifetime lactations of the cows was highly significant, 
indicating that lifetime BLV effects on the total milk production was dependent on the 
lactation in which the study cows were culled or died. Only BLV-positive cows with 
short longevity (2 and 3 lactations) had substantially lower total milk productions 
compared with their negative counterparts. As the cows lived longer (> 3 life lactations), 
the differences in lifetime milk production between the two cohorts were no longer 
substantial. 
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Regarding the chronic nature and gradual progress of BLV infection, evaluating 
its economic impacts over the lifetime of dairy cows is very informative. The design of 
our study was well-suited for describing the potential causal association between BLV 
infection and the corresponding production and longevity effects. Seropositive cows had 
consistently shorter lifespan compared with their negative counterparts, suggesting that 
the infection could be one of the main causes of premature culling (or death) at any age 
groups of cows. 
7.3 Carryover of BLV-antibodies in shared milk meters 
The focus for Chapter 4 was two-fold. The first objective was to assess the 
potential for carryover of antibodies against BLV in milk samples obtained from shared 
meters. The study included 236 paired milk samples from 8 dairy farms in Prince Edward 
Island. Two simultaneous milk samples, one hand-collected at the beginning of milking, 
and the other from the corresponding milk meter were taken from all lactating cows that 
were milked at the selected meters. The sequence of cows using each meter was recorded. 
All samples were tested for BLV antibodies using a commercial indirect ELISA. 
Antibody carryover potential was assessed in meter-collected samples which were 
preceded by other cows using the same meters. At the standard cut-off value of the 
diagnostic test (milk ELISA), 46.6% of the hand-collected, and 57.6% of the meter-
collected samples were positive. For low-titer cows (e.g. true negatives), the likelihood of 
antibody carryover significantly increased as the titer of preceding cows increased, while 
this change was not substantial for high-titer cows. In addition, the odds of obtaining 
false diagnoses in meter-positive samples became larger with increasing titers in the 
preceding cows. 
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With respect to the results from the first part of this Chapter, the second objective 
was to determine if adjustment of the diagnostic test cut-off value would improve the test 
characteristics for meter-collected results. For this purpose, a receiver operating 
characteristic (ROC) curve analysis was carried out to define the optimal cut-point which 
would result in lower number of false diagnoses. Based on the original kit and the 
adjusted cut-off values for the meter-collected samples, three categories of ELISA results 
(negative, suspicious, and positive) were defined and a retest was recommended on the 
suspicious samples. 
Carryover of BLV antibodies at shared milk meters was significant. For low-titer 
cows (e.g., true negatives), the carryover effect was positively associated with the titer of 
the preceding cows. This could result in generating false-positive results in the BLV 
antibody-ELISA test on meter-collected samples from dairy herd improvement (DHI) 
procedures. For meter-collected samples, if we only rely on the dichotomous test results 
with the original cut-off, the consequences can be economically substantial. Thus, 
defining a suspicious category for the ELISA titers and recommending a retest on the 
samples falling within this range would be very helpful in reducing the false positive rate. 
7.4 Predicting within-herd prevalence of BLV infection 
The objectives for Chapter 5 were to: 1) determine the prevalence of BLV 
infection at the herd level using a BTM antibody ELISA in the Maritime region of 
Canada; and 2) develop applied statistical models for predicting within-herd prevalence 
of BLV infection using the BTM antibody levels.  
To detect BLV infection and the antibody levels, a census was implemented on 
BTM samples from all dairy farms in the Maritime region (3 rounds of sampling on 623 
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farms). Another round of BTM sampling was coincided with individual cow sampling 
(all cows that contributed milk to the fourth BTM) in 90 selected herds. Herd-level 
prevalence of BLV in the Maritime region was 90.8%. In the individual testing, 30.4% of 
cows were positive. Prevalence of infection with BLV at the herd and cow levels on dairy 
farms of the Maritime region of Canada was very high, indicating the necessity for a 
comprehensive response. Obtaining an estimate of the number of infected cows on a farm 
would be a fundamental step towards adopting appropriate control or eradication 
strategies for that farm. 
The statistical models developed in this study were able to predict true within-
herd prevalence of BLV reasonably well. Predictions from the models were particularly 
accurate for low-to-medium spectrums of the BTM titers. The model including all BTM 
tests (4 rounds of sampling) as the predictor had the best fit, although the models using 2 
and 3 BTM tests provided similar results to 4 repeated tests. However, the choice of one 
model would primarily depend on different purposes of BTM testing in dairy farms with 
various levels of BLV infection prevalence (e.g. for reducing high-prevalence of BLV, or 
eliminating the infection from low-prevalence herds). The presented methodology offers 
many advantages, including being convenient (BTM samples can easily be accessed), 
efficient (as few as 2 BTM samples could be used), and inexpensive (individual cow 
samples not needed). Therefore, in order to motivate dairy producers to take decisive 
control measures against BLV, the methodology could readily be integrated into future 
BLV control and surveillance programs. Application of the presented approach could 
cautiously be extended to dairy farms from other regions with similar structure and 
management strategies. 
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7.5 Diagnostic performance of an ELISA for herd-level application  
The focus for Chapter 6 was to assess the diagnostic performance (sensitivity and 
specificity) of a commercially available ELISA for detecting bovine leukemia virus 
(BLV) antibodies in bulk-tank milk (BTM) samples collected from dairy herds in eastern 
Canada. Of 133 tested herds from eastern Canada, 108 herds were found to be truly 
infected. Of 8358 tested lactating cows, 31.8% were positive to BLV milk antibodies in 
the individual cow testing. The optimal cut-point for BTM ELISA titers was achieved at 
5 percent positivity. At this cut-point, sensitivity and specificity of the BTM ELISA were 
estimated at 0.972 (95% CI: 0.921 – 0.994) and 1 (95% CI: 0.863 – 1), respectively. 
Application of the ELISA test to BTM samples at the cut-point of 5 (which was 
also the manufacturer’s recommendation) generated reasonably valid results. Farmers 
whose farms are free from BLV and would desire to maintain their negative status or 
those who wish to monitor their decreasing trend of BLV prevalence on their farms (due 
to taken control measures) could efficiently adopt ongoing monitoring using the BTM 
ELISA test over appropriate time-intervals. Application of the BTM ELISA in other 
regions (with large herds in particular) should be validated before applying to future 
surveillance programs. 
7.6 A provisional example for a comprehensive control/eradication program  
Combining all of the findings from this thesis with the results from historic 
studies, we could design and conduct a comprehensive control/eradication program for 
BLV at herd, regional, or even national level in Canada. A provisional example for such a 
program is demonstrated in Figure 7.1. From the figure, the following steps could be 
taken towards effective control and finally eradication of BLV: 
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1. Preliminary screenings for antibodies against BLV using BTM ELISA (Svanova 
test kit, Chapters 4-6); BTM sampling and testing are repeated on a regular basis 
(recommendation: at least 2 or 3 samples with 2-month intervals);  
2. If the results (from Step 1) are negative, BTM ELISA monitoring is continued on 
a regular basis with appropriate time intervals. Meanwhile, rigorous biosecurity measures 
must be taken to inhibit the introduction of BLV to these negative herds. The consistently 
negative herds may pursue a BLV-free certificate; 
3. If the results (from Step 1) are positive, the developed statistical models in 
Chapter 5 will be applied to estimate the within-herd prevalence of the infection; 
4. If the within-herd prevalence is at a very low level (only a few positive animals 
are present in the herd), test and removal strategy may be justified (Section 1.1.7). For 
this purpose, individual animal sampling and testing (milk and serum ELISA) would be 
necessary. The infection could be eliminated from these herds and then they could join 
the negative category of herds; 
5. If the within-herd prevalence is at relatively low levels (e.g. < 20%), test and 
segregation strategy could be adopted. For this purpose, individual animal sampling and 
testing (milk and serum ELISA) would be necessary. Segregation of positive cows from 
the negative ones is not always a practical option in some herds in Canada. In this case, 
one recommendation could be finding and separating cows, which potentially pose a 
greater risk to their susceptible herd mates (e.g. PL cows). To detect these animals, 
repeated testing, along with differential blood cell count on cows with high levels of 
antibodies could be very helpful. Segregating cows with consistently high levels of 
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antibodies and/or PL cows is recommended (when this strategy is not justifiable to be 
extended to all of the infected cows within a herd); 
6. If the within-herd prevalence is estimated at medium levels or higher (e.g. > 20), 
suitable management interventions which can inhibit the potential movement of 
contaminated blood between infected and non-infected animals (such as using single-use 
needles and rectal sleeves, as well as purchasing BLV-negative cows; Chapters 1 and 2) 
are recommended. In this case, the goal would be to decrease the within-herd prevalence 
of BLV during a reasonable time period (e.g. 2 years). In order to assess the efficacy of 
the adopted measures, regular BTM screening (as explained above) would be necessary. 
Subsequent to reducing the prevalence to low levels, the approach explained in Step 5 
could be pursued;   
7. Evaluations of the efficacy and the corresponding cost-benefit analyses would be 
imperative at different steps of this comprehensive control/eradication program. 
7.7 Current research limitations and future directions 
Overall, with respect to the high prevalence of BLV infection across Canada, the 
outlined adverse economic impacts, and its increasing importance, pursuing broad-based, 
efficient control programs is necessary. The final goal of this thesis was to lay a proper 
foundation for developing efficient control and eradication programs for BLV in Canada. 
Despite the accomplishments of the current work, there are still some challenges and 
uncertainties regarding BLV infection control.  
Herd-level risk factors and economic impacts of BLV infection (presented in 
Chapters 2 and 3) were based upon the diagnostic tests, which were carried out between 
1998 and 2003. There is always a need for real-time evaluations of the economic impacts 
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of the infection in a specific herd or region given the fact that most control and 
eradication options are highly dependent on the within-herd prevalence of the infection, 
value of cows within a herd, and the management structure of the herd (Radostits et al., 
2006; Bartlett et al., 2014). In order to make optimal decisions on adopting the most 
suitable strategy against BLV, estimating the within-herd prevalence and implementing a 
cost-benefit analysis in the real-time (i.e. before and concurrent with an undertaken 
control/eradication program) are imperative. 
Growing concerns regarding carryover or cross-contamination of the samples 
from shared milking equipment was addressed in Chapter 4. Over the last several years, 
meter-collected samples have been used to reduce the cost and time in screening for 
important diseases of dairy cattle, and this utilization is increasing. Our findings on 
carryover of BLV-antibodies could logically be extended to other commonly tested 
pathogens. Therefore, further similar studies focusing on each specific diagnostic target 
(e.g. antibodies against a particular pathogen) are essential to the success of related 
surveillance programs. The carryover effects should be measured and addressed in a 
distinct way for each pathogen, based on its characteristics, the diagnostic tests used, and 
the corresponding program. Adjusting the assay cut-off values could be one of the most 
practical approaches for reducing the false diagnostic rates due to carryover. 
The prediction models developed in Chapter 5 could readily be integrated in the 
future surveillance programs for BLV. Hence, it could act as compelling motivation for 
producers to take some rigorous measures while saving a great deal of time, effort, and 
cost. The statistical models were well-suited for the herds from Atlantic Canada. To 
generate the most efficient models, with respect to the dairy herd structure and 
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management practices in other regions (or countries), similar research on developing and 
validating such predictive models is recommended. 
Appropriate diagnostic tests play a critical role towards ensuring the application 
and success of any surveillance programs. For BLV, milk-ELISA is the commonly used 
test with excellent accuracy at individual level application. Our findings in Chapter 6 
emphasized the importance of validating the screening tests. When a diagnostic setting 
(e.g. a commercial test kit) is to be applied to a particular region (or country) on large-
scale for the first time, assessing its validity on a representative sample of herds could be 
very informative and substantially reduce the costs associated with potential false 
diagnoses. 
Using the obtained results from this thesis and preceding studies (VanLeeuwen et 
al., 2001; VanLeeuwen et al., 2005; Tiwari et al., 2005; Scott et al., 2006; Tiwari et al., 
2007; Vanleeuwen et al., 2010; Sorge et al., 2011), a reasonably strong foundation has 
been laid towards defining and conducting cost-efficient control programs for BLV in 
Canada. Subsequent to the implementation of future programs, additional longitudinal 
studies on their efficacy will be necessary. For instance, if a producer (who has a high-
prevalence dairy herd) is implementing some recommended control measures (e.g. 
purchasing negative animals, using single-use needles and obstetric sleeves, etc.) to 
reduce the prevalence of BLV infection on his farm, he could monitor the antibody levels 
of BTM on a regular basis (according to our developed methodology/models in Chapter 
5). With this, he would be able to assess the efficacy of the adopted strategies in 
decreasing the level of prevalence over defined time intervals (e.g. during 2 years or 
more). 
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Producing efficient vaccines against BLV could be a real advancement in the 
future control campaigns. Many previous attempts to develop an effective vaccine against 
BLV have been unsuccessful, mostly due to incomplete or transient stimulation of the 
host immune response. Some promising results have recently been achieved in 
developing attenuated clone (but replication competent) that protects against the virus in 
dairy herds (Gutiérrez et al., 2014; Frie and Coussens, 2015). An ideal BLV vaccine 
would have to be non-infectious, non-oncogenic, and should not interfere with the tests 
commonly used to detect the infection (Radostits et al., 2006). Further studies on 
different aspects of the vaccine development would be immensely beneficial to pursuing 
efficient control and eradication programs in Canada and other endemic areas. 
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Figure 7.1.  A provisional example of a comprehensive control/eradication program for 
enzootic bovine leukosis designed using the findings from the current research and 
historic studies in Canada. This program is based on bulk-tank milk (BTM) screening and 
monitoring for bovine leukemia virus antibodies applying the test kit and methodology 
outlined in Chapter 5. Please visit Section 7.7 for the step-by-step explanations.  
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APPENDIX A  
The political map of Canada, displaying all provinces (10), and territories (3). Adapted 
from http://en.wikipedia.org/wiki/File:Political_map_of_Canada.png (last access on 
September 19, 2015). 
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APPENDIX B 
Prediction of the within-herd prevalence of infection with bovine leukemia virus (Y axis), 
versus the repeated bulk-tank milk ELISA titers (percent positivity; X axis), from four 
developed models in the study (scenarios X1, X2, X4, and X6). Dashed lines around the 
solid prediction-lines represent the 95% confidence intervals for the predictions (after 
back-transformation to original scale). Each point represents one of the 90 selected farms 
from the Maritime region of Canada. X1: using concurrent scenario; X2: mean of rounds 
3 and 4; X4: mean of rounds 1, 3, and 4; X6: mean of rounds 1, 2, and 3. 
 
 
 
